0001654954-24-003942.txt : 20240329 0001654954-24-003942.hdr.sgml : 20240329 20240329130617 ACCESSION NUMBER: 0001654954-24-003942 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 38 CONFORMED PERIOD OF REPORT: 20231231 FILED AS OF DATE: 20240329 DATE AS OF CHANGE: 20240329 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Green Planet Bio Engineering Co. Ltd. CENTRAL INDEX KEY: 0001392449 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 371532842 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-52622 FILM NUMBER: 24803262 BUSINESS ADDRESS: STREET 1: 20807 BISCAYNE BLVD. STREET 2: SUITE 203 CITY: AVENTURA STATE: FL ZIP: 33180 BUSINESS PHONE: 786-279-2900 MAIL ADDRESS: STREET 1: 20807 BISCAYNE BLVD. STREET 2: SUITE 203 CITY: AVENTURA STATE: FL ZIP: 33180 FORMER COMPANY: FORMER CONFORMED NAME: Mondo Acquisition II, Inc. DATE OF NAME CHANGE: 20070308 10-K 1 gplb_10k.htm FORM 10-K gplb_10k.htm

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 10-K

 

(Mark One)

 

Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

 

 

For the Fiscal Year Ended December 31, 2023 

 

or

 

Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

 

 

For the transition period from _________ to _________  

     

Commission file number 000-52622

 

GREEN PLANET BIOENGINEERING CO., LTD.

(Exact Name of Registrant as Specified in its charter)

 

Delaware

 

37-1532842

(State or Other Jurisdiction of 

Incorporation or organization)

 

(I.R.S. Employer

Identification No.)

 

 

 

20807 Biscayne Blvd., Suite 203,

Aventura, Florida

 

33180

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (786) 279-2900

 

Securities registered pursuant to Section 12(b) of the Act: NONE

 

Securities registered pursuant to Section 12(g) of the Act: NONE

 

Indicate by check mark whether the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes  ☐ No  ☒

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Yes  ☐ No  ☒

 

Note – Checking the box above will not relieve any registrant required to file reports pursuant to Section 13 or 15(d) of the Exchange Act from their obligations under those Sections.

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes   ☒  No   ☐

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes  ☒ No  ☐

 

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. ☐

 

Indicate by checkmark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

(Do not check if a smaller reporting company)

 

 

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) Yes   No  ☐

 

The aggregate market value of the registrant’s common stock held by non-affiliates was $722,205 based on the closing sale price of common stock on June 30, 2023. The number of shares of common stock outstanding as of March 29, 2024 was 20,006,402.

 

Audit firm ID: 5036

 

 

 

 

TABLE OF CONTENTS

 

PART I

 

 

 

 

 

 

 

 

 

Item 1. 

Business

 

4

 

Item 1A.

Risk Factors

 

4

 

Item 1B.

Unresolved Staff Comments

 

5

 

Item 2.

Properties

 

5

 

Item 3.

Legal Proceedings

 

5

 

Item 4.

Mine Safety Disclosures

 

5

 

 

 

 

 

 

PART II

 

 

 

 

 

 

 

 

 

Item 5.

Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

 

6

 

Item 6.

Selected Financial Data

 

6

 

Item 7.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

6

 

Item 7A.

Quantitative and Qualitative Disclosures about Market Risk

 

7

 

Item 8.

Financial Statements

 

8

 

Item 9.

Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

 

17

 

Item 9A.

Controls and Procedures

 

17

 

Item 9B.

Other Information

 

17

 

 

 

 

 

 

PART III

 

 

 

 

 

 

 

 

 

Item 10.

Directors, Executive Officers and Corporate Governance

 

18

 

Item 11.

Executive Compensation

 

19

 

Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

 

19

 

Item 13.

Certain Relationships and Related Transactions, and Director Independence

 

19

 

Item 14.

Principal Accounting Fees and Services

 

19

 

 

 

 

 

 

PART IV

 

 

 

 

 

 

 

 

 

Item 15.

Exhibits and Financial Statement Schedules

 

20

 

 

 

 

 

 

Signatures

 

 

21

 

 

 
2

Table of Contents

  

 FORWARD-LOOKING STATEMENTS

 

This Annual Report on Form 10-K contains forward-looking statements.  These statements involve risks and uncertainties, including, among other things, statements regarding our business strategy, future revenues and anticipated costs and expenses.  Such forward-looking statements include, among others, those statements including the words “expects,” “anticipates,” “intends,” “believes,” “may,” “will,” “should,” “could,” “plans,” “estimates,” and similar language or negative of such terms.  Our actual results may differ significantly from those projected in the forward-looking statements.  Factors that might cause or contribute to such differences include, but are not limited to, those discussed in Item 7 “Management’s Discussion and Analysis of Financial Condition and Results of Operations.”  You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this report.  Although we believe that the expectations reflected in the forward-looking statements are reasonable, we do not know whether we can achieve positive future results, levels of activity, performance, or goals.  Actual events or results may differ materially.  We undertake no obligation to publicly release any revisions to the forward-looking statements or reflect events or circumstances taking place after the date of this document.

 

 
3

Table of Contents

 

PART I

 

ITEM 1. BUSINESS

 

Description of Business

 

Green Planet Bioengineering Co., Ltd. (“Green Planet” or “Company”) operates as a public reorganized shell corporation with the purpose to acquire or merge with an existing business operation.

 

Our History

 

Mondo Acquisition II, Inc. was incorporated in the State of Delaware on October 30, 2006 and changed the name to Green Planet Bioengineering Co., Ltd. on October 2, 2008. In October 2008, the Company acquired Elevated Throne Overseas Ltd, a company incorporated in British Virgin Islands, and its subsidiaries (“Elevated Throne”) which operated the business in the agritech sector in the People’s Republic of China. The Company divested Elevated Throne to One Bio, Corp. (“ONE”) on April 14, 2010.  

 

In March 2012, Global Funds Holdings Corp. (“Global Funds”) an Ontario, Canada corporation became a majority stockholder of the Company.

 

The Company operates as a public organized shell corporation with the purpose to acquire or merge with an existing business operation.  The Company’s activities are subject to significant risks and uncertainties, as their ability to implement and execute future business plans and generate sufficient business revenue is directly influenced by their ability to secure adequate financing or find profitable business opportunities.

 

ITEM 1A. RISK FACTORS

 

You should consider carefully each of the following business and investment risk factors and all of the other information in this report. If any of the following risks and uncertainties develops into actual events, the business, financial condition or results of our operations could be materially and adversely affected. If that happens, the trading price of our shares of common stock could decline significantly. The risk factors below contain forward-looking statements regarding our business. Actual results could differ materially from those set forth in the forward-looking statements. See "Special Note Regarding Forward-Looking Information."

 

Risk Related to the Company's Future Business

 

We give no assurances that any plans for future business will be implemented if we do not secure adequate financing or find profitable business opportunities.

 

Our ability to implement and execute our future business plans and ultimately generate enough business revenue is directly influenced by our ability to secure adequate financing or find profitable business opportunities.  If we do not receive funding from future investors or find profitable business opportunities, we will experience delays in our business plans and, ultimately, in our profitability going forward. 

 

We will continue to incur significant costs as a result of remaining as a public reorganized company, and management will be required to devote substantial time to new compliance requirements.

 

As a public company, we incur significant legal, accounting and other expenses under the Sarbanes-Oxley Act of 2002, together with rules implemented by the Securities and Exchange Commission and applicable market regulators. These rules impose various requirements on public companies, including requiring certain corporate governance practices. Management and other personnel will need to devote a substantial amount of time to these new compliance requirements. Moreover, these rules and regulations will increase our legal and financial compliance costs and will make some activities more time consuming and costlier.

 

In addition, the Sarbanes-Oxley Act requires, among other things, that we maintain effective internal controls for financial reporting and disclosure controls and procedures. In particular, we must perform system and process evaluations and testing of our internal controls over financial reporting to allow management and our registered independent public accounting firm to report on the effectiveness of our internal controls over financial reporting, as required by Section 404 of the Sarbanes-Oxley Act. Our testing, or the subsequent testing by our registered independent public accounting firm, may reveal deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses. Compliance with Section 404 may require that we incur substantial accounting expenses and expend significant management efforts. If we are not able to comply with the requirements of Section 404 in a timely manner, or if our registered independent accountants later identify deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses, the market price of our stock could decline and we could be subject to sanctions or investigations by the SEC or other applicable regulatory authorities.

 

 
4

Table of Contents

 

Risks Related to the Common Stock

 

There is currently no trading market for our common stock.

 

Outstanding shares of our common stock cannot be offered, sold, pledged or otherwise transferred unless subsequently registered pursuant to, or exempt from registration under, the Securities Act and any other applicable federal or state securities laws or regulations. These restrictions will limit the ability of our stockholders to liquidate their investment.

 

We have not paid and do not anticipate paying any dividends on our common stock; therefore, our securities could face devaluation in the market.

 

We have paid no dividends on our common stock to date and it is not anticipated that any dividends will be paid to holders of our common stock in the foreseeable future. While our dividend policy will be based on the operating results and capital needs of the business, it is anticipated that any earnings will be retained to finance our future expansion and for the implementation of our new business plan. Lack of a dividend can further affect the market value of our common stock, and could significantly affect the value of any investment in us.

 

Penny Stock Regulations

 

The SEC has adopted regulations which generally define "penny stock" to be an equity security that has a market price of less than $5.00 per share. Our common stock, when and if a trading market develops, may fall within the definition of penny stock and subject to rules that impose additional sales practice requirements on broker-dealers.

 

For transactions covered by these rules, the broker-dealer must make a special suitability determination for the purchase of such securities and have received the purchaser's prior written consent to the transaction. Additionally, for any transaction, other than exempt transactions, involving a penny stock, the rules require the delivery, prior to the transaction, of a risk disclosure document mandated by the Securities and Exchange Commission relating to the penny stock market. The broker-dealer also must disclose the commissions payable to both the broker-dealer and the registered representative, current quotations for the securities and, if the broker-dealer is the sole market-maker, the broker-dealer must disclose this fact and the broker-dealer's presumed control over the market. Finally, monthly statements must be sent disclosing recent price information for the penny stock held in the account and information on the limited market in penny stocks. Consequently, the "penny stock" rules may restrict the ability of broker-dealers to sell our common stock and may affect the ability of investors to sell their common stock in the secondary market.

 

ITEM 1B. UNRESOLVED STAFF COMMENTS

 

None

 

ITEM 2. PROPERTIES

 

None

 

ITEM 3. LEGAL PROCEEDINGS

 

None

 

ITEM 4. MINE SAFETY DISCLOSURES

 

None

 

 
5

Table of Contents

 

PART II

 

ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

 

The Company’s common stock is available for quotation on the Over the Counter Bulletin Board under the symbol “GPLB.PK.” There is no assurance that the company’s stock will continue to be quoted or that any liquidity will exist for our stockholders.

 

The following table shows, for each quarter of fiscal 2023 and 2022 the high and low closing price per share of common stock as reported on the Over the Counter Bulletin Board. The following quotations reflect inter-dealer prices, without retail mark-up, mark-down or commission, and may not represent actual transactions. The source of this information is NASDAQ Over the Counter Bulletin Board Research Report.

 

 

 

2023

 

 

2022

 

Quarter Ended

 

High

 

 

Low

 

 

High

 

 

Low

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Fourth Quarter

 

$1.000

 

 

$0.061

 

 

$2.450

 

 

$2.000

 

Third Quarter

 

 

1.100

 

 

 

0.172

 

 

 

2.600

 

 

 

0.680

 

Second Quarter

 

 

1.100

 

 

 

0.161

 

 

 

0.810

 

 

 

0.280

 

First Quarter 

 

 

 2.500

 

 

 

 0.200

 

 

 

 0.350

 

 

 

 0.180

 

 

 

We have never declared or paid any cash dividends on our common stock.

 

ITEM 6. SELECTED FINANCIAL DATA

 

Not applicable.

 

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

Overview

 

The Company operates as a public reorganized corporation with the business purpose to acquire or merge with an existing business operation.

 

Results of Operations

 

The Company did not have any operations and did not have any operating revenues during the years ended December 31, 2023 and 2022, respectively.

 

Total expenses for the years ended December 31, 2023 and 2022 were $47,670 and $32,533, respectively. The majority of these expenses primarily constituted administrative expenses related to accounting and compliance with the Exchange Act.

 

Liquidity and Capital Resources

 

The Company had no active business operation during the year. Accordingly, all the Company’s cash flow needs for 2023 were provided solely by a related party of Global Funds to pay expenses necessary as a public company.

 

Going forward, the Company will continue to source adequate funding from future investors to execute business opportunities when they arise in the future. However, such funding and business opportunities will rely entirely on the prevailing circumstances when the funding or profitable business opportunities are identified. If such opportunities are not identified in the near term, the Company will experience delay in effecting its business plans. 

 

The financial statements have been prepared assuming that the Company will continue as a going concern. The Company is currently a public reorganized shell corporation and has no current business activity. The Company’s ability to continue as a going concern is dependent on continued support from Global Funds, the majority stockholder. This gives rise to substantial doubt about the Company’s ability to continue as a going concern.

 

 
6

Table of Contents

 

Critical Accounting Policies and Estimates

 

We prepare our financial statements in conformity with accounting principles generally accepted (“GAAP”) in the United States of America. As such, we are required to make certain estimates, judgments and assumptions that we believe are reasonable based upon historical experience, current trends and other factors.  As such, actual results could differ from our estimates and such differences could be material.  We have identified below the critical accounting policies which are assumptions made by management about matters that are uncertain and are of critical importance in the presentation of our financial position, results of operations and cash flows.  On a regular basis, we review our accounting policies and how they are applied and disclosed in the financial statements.

 

The preparation of financial statements in conformity with GAAP in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, as well as the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.  Actual results could differ from those estimates. 

 

Off-Balance Sheet Arrangements

 

There are no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

 

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

None

 

 
7

Table of Contents

 

ITEM 8. FINANCIAL STATEMENTS

      

INDEX TO FINANCIAL STATEMENTS

 

 

 

Report of Independent Registered Public Accounting Firms

 

 

9

 

Financial Statements:

 

 

 

 

Balance Sheets

 

 

10

 

Statements of Operations

 

 

11

 

Statements of Cash Flows

 

 

12

 

Statements of Changes in Stockholders’ Deficit

 

 

13

 

Notes to the Financial Statements

 

14

 

 

 
8

Table of Contents

 

gplb_10kimg7.jpg

    

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

    

To the Board of Directors and Stockholders of

Green Planet Bioengineering Co., Ltd.

 

Opinion on the Financial Statements

 

We have audited the accompanying balance sheets of Green Planet Bioengineering Co., Ltd. (the Company) as of December 31, 2023 and 2022, and the related statements of operations, stockholders' deficit, and cash flows for each of the years in the two-year period ended December 31, 2023, and the related notes (collectively referred to as the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the years in the two-year period ended December 31, 2023, in conformity with accounting principles generally accepted in the United States of America.

 

Explanatory Paragraph- Going Concern

 

The accompanying financial statements have been prepared assuming the Company will continue as a going concern. As discussed in Note 3 to the financial statements, the Company currently a public reorganized shell corporation and has no current business activity with losses of $ 47,670 as of December 31, 2023. The Company's ability to continue as a going concern is dependent on continued support from a related party. These factors raise substantial doubt about the Company's ability to continue as a going concern. This gives rise to substantial doubt about the Company's ability to continue as a going concern for a period of twelve months after the issuance of these financial statements. Management's plans concerning these matters are also described in Note 3. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Basis for Opinion

 

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

Critical Audit Matters

 

Critical audit matters are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments.

 

We determined that there were no critical audit matters.

 

/s/ Assurance Dimensions

We have served as the Company's auditor since 2022.

Margate, Florida

March 29, 2024

 

 
9

Table of Contents

 

Green Planet Bioengineering Co., Ltd

Balance Sheets

(Stated in US Dollars)

 

 

 

December 31,

 

 

December 31,

 

 

 

2023

 

 

2022

 

 

 

 

 

 

 

 

ASSETS

 

 

 

 

 

 

Current assets

 

 

 

 

 

 

Cash

 

$-

 

 

$-

 

 

 

 

 

 

 

 

 

 

TOTAL CURRENT ASSETS

 

$-

 

 

$-

 

 

 

 

 

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS’ DEFICIT

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

LIABILITIES

 

 

 

 

 

 

 

 

Current liabilities

 

 

 

 

 

 

 

 

Accounts payable and accrued liabilities

 

$5,000

 

 

$-

 

Amount due to a related party

 

 

424,590

 

 

 

381,920

 

 

 

 

 

 

 

 

 

 

TOTAL CURRENT LIABILITIES

 

 

429,590

 

 

 

381,920

 

 

 

 

 

 

 

 

 

 

STOCKHOLDERS’ DEFICIT

 

 

 

 

 

 

 

 

Preferred stock : par value of $0.001 per share, Authorized: 10,000,000 shares at December 31, 2023 and December 31, 2022 Issued and outstanding : 0 shares at December 31, 2023 and December 31, 2022

 

 

-

 

 

 

-

 

Common stock : par value $0.001 per share Authorized : 250,000,000 shares at December 31, 2023 and December 31, 2022 Issued and outstanding : 20,006,402 shares at December 31, 2023 and December 31, 2022

 

 

20,006

 

 

 

20,006

 

Additional paid-in capital

 

 

609,614

 

 

 

609,614

 

Accumulated deficit

 

 

(1,059,210 )

 

 

(1,011,540 )

 

 

 

 

 

 

 

 

 

TOTAL STOCKHOLDERS’ DEFICIT

 

 

(429,590 )

 

 

(381,920 )

 

 

 

 

 

 

 

 

 

TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT

 

$-

 

 

$-

 

 

See Notes to the Financial Statements

 

 
10

Table of Contents

  

Green Planet Bioengineering Co., Ltd

Statements of Operations

(Stated in US Dollars)

 

 

 

Years ended December 31,

 

 

 

2023

 

 

2022

 

 

 

 

 

 

 

 

Administrative expenses

 

$(47,370)

 

$(32,533)

Interest expenses

 

 

(300)

 

 

-

 

 

 

 

 

 

 

 

 

 

Loss before income taxes

 

 

(47,670)

 

 

(32,533)

Provision for income taxes

 

 

-

 

 

 

-

 

 

 

 

 

 

 

 

 

 

Net loss

 

$(47,670)

 

$(32,533)

 

 

 

 

 

 

 

 

 

Loss per share

 

 

 

 

 

 

 

 

-Basic and diluted

 

 $

                     (*

 

$

                      (*

 

 

 

 

 

 

 

 

 

Weighted average number of shares outstanding

 

 

 

 

 

 

 

 

-Basic and diluted

 

 

20,006,402

 

 

 

20,006,402

 

 

*  Less than $.01, per share

 

See Notes to the Financial Statements

 

 
11

Table of Contents

 

Green Planet Bioengineering Co., Ltd

Statements of Cash Flows

(Stated in US Dollars)

 

 

 

Year ended December 31,

 

 

 

2023

 

 

2022

 

Cash flows from operating activities

 

 

 

 

 

 

Net loss

 

$(47,670)

 

$(32,533)

Changes in operating assets and liabilities :

 

 

 

 

 

 

 

 

Accounts payable and accrued liabilities

 

 

5,000

 

 

 

-

 

 

 

 

 

 

 

 

 

 

Net cash flows used by operating activities

 

$(42,670)

 

$(32,533)

 

 

 

 

 

 

 

 

 

Cash flows from investing activities

 

 

-

 

 

 

-

 

 

 

 

 

 

 

 

 

 

Cash flows from financing activities

 

 

 

 

 

 

 

 

Amount due to a related company

 

$42,670

 

 

$32,533

 

 

 

 

 

 

 

 

 

 

Net cash flows provided by financing activities

 

 

42,670

 

 

 

32,533

 

 

 

 

 

 

 

 

 

 

Net change in cash

 

 

-

 

 

 

-

 

Cash - beginning of period

 

 

-

 

 

 

-

 

 

 

 

 

 

 

 

 

 

Cash - end of period

 

$-

 

 

$-

 

 

 

 

 

 

 

 

 

 

Supplemental disclosures for cash flow information:

 

 

 

 

 

 

 

 

Cash paid for interest

 

$300

 

 

$-

 

Cash paid for income taxes

 

$-

 

 

$-

 

  

See Notes to the Financial Statements

 

 
12

Table of Contents

 

Green Planet Bioengineering Co., Ltd

Statements of Changes in Stockholders’ Deficit

(Stated in US Dollars)

 

 

 

Preferred Stock

 

 

Common Stock

 

 

 

 

 

 

 

 

 

Number

 

 

 

 

Number

 

 

 

 

Additional

paid-in

 

 

Accumulated

 

 

 

 

 

 of shares

 

 

Amount

 

 

of shares

 

 

Amount

 

 

capital

 

 

deficit

 

 

Total

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance, December 31, 2021

 

 

-

 

 

$-

 

 

 

20,006,402

 

 

$20,006

 

 

$609,614

 

 

$(979,007)

 

$(349,387)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(32,533)

 

 

(32,533)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance, December 31, 2022

 

 

-

 

 

 

 

 

 

$20,006,402

 

 

$20,006

 

 

$609,614

 

 

$(1,011,540)

 

$(381,920)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(47,670)

 

 

(47,670)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance, December 31, 2023

 

 

-

 

 

 

 

 

 

$20,006,402

 

 

$20,006

 

 

$609,614

 

 

$(1,059,210)

 

$(429,590)

 

See Notes to the Financial Statements

 

 
13

Table of Contents

 

Green Planet Bioengineering Co., Ltd.

Notes to the Financial Statements

1. General Information

 

Mondo Acquisition II, Inc. was incorporated in the State of Delaware on October 30, 2006 and the name was changed to Green Planet Bioengineering Co., Ltd. (“Company”) on October 2, 2008. In October 2008, the Company acquired Elevated Throne Overseas Ltd, incorporated in British Virgin Islands, and its subsidiaries (“Elevated Throne”) and operated the business in the agritech sector in the People’s Republic of China. The Company divested Elevated Throne to One Bio, Corp. (“ONE”) on April 14, 2010. 

 

In March 2012, Global Funds Holdings Corp. (“Global Funds”) an Ontario, Canada corporation became a majority stockholder of the Company.

 

The Company operates as a public reorganized shell corporation with the purpose to acquire or merge with an existing business operation.   The Company's activities are subject to significant risks and uncertainties, as their ability to implement and execute future business plans and generate sufficient business revenue is directly influenced by their ability to secure adequate financing or find profitable business opportunities. 

 

2. Summary of Significant Accounting Policies

 

Basis of Presentation

The financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”).

 

Use of Estimates

The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses for the years reported.  Actual results could differ from those estimates.  Significant items that require estimates were accruals of liabilities.

 

Cash and Cash Equivalents

Cash and cash equivalents include all cash, deposits in banks and other highly liquid investments with initial maturities of three months or less to be cash equivalents.  Balances of cash and cash equivalents in financial institutions does not exceed the government-insured limits as of December 31, 2023.

 

Income Taxes

The Company accounts for income taxes in accordance with FASB ASC Topic 740 “Income Taxes” under which deferred tax assets and liabilities are determined based on temporary differences between accounting and tax bases of assets and liabilities and net operating loss and credit carry forwards, using enacted tax rates in effect for the year in which the differences are expected to reverse.  Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized.  A provision for income tax expense is recognized for income taxes payable for the current period, plus the net changes in deferred tax amounts.  Any interest and penalties are expensed in the year that the Notice of Assessment is received. The Company’s practice is to recognize interest and/or penalties related to income tax matters as interest expense.

 

U.S. GAAP provides guidance for how uncertain tax positions should be recognized, measured, presented and disclosed in the financial statements. U.S. GAAP requires the evaluation of tax positions taken or expected to be taken in the course of preparing the Company’s tax returns to determine whether the tax positions are “more-likely-than-not” of being sustained by the applicable tax authority. Tax positions not deemed to meet a “more-likely-than-not” threshold would be recorded as a tax expense in the current year. The Company identifies its major tax jurisdictions as the U.S. for Federal tax purposes and Delaware for state tax purposes. The Company has concluded that there are no significant tax positions requiring recognition, measurement or disclosure in the financial statements for all open tax years. Tax years which are considered open by the relevant jurisdiction are subject to potential examination. 

 

Loss Per Share

Earnings per share is reported in accordance with FASB ASC Topic 260 “Earnings per Share” which requires dual presentation of basic earnings per share (“EPS”) and diluted EPS on the face of all statements of earnings, for all entities with complex capital structures.  Diluted EPS reflects the potential dilution that could occur from common shares issuable through the exercise or conversion of stock options, restricted stock awards, warrants and convertible securities. In certain circumstances, the conversion of these options, warrants and convertible securities are excluded from diluted EPS if the effect of such inclusion would be anti-dilutive.  Fully diluted EPS is not provided, when the effect is anti-dilutive. When the effect of dilution on loss per share is anti-dilutive, diluted loss per share equals the loss per share. As of December 31, 2023 and 2022 the Company does not have any common share equivalents outstanding.

 

 
14

Table of Contents

 

2. Summary of Significant Accounting Policies – continued

 

Fair Value Measurements

FASB ASC Topic 820, “Fair Value Measurements and Disclosures” defines fair value, establishes a framework for measuring fair value in accordance with U.S. GAAP, and expands disclosures about fair value measurements. Investments measured and reported at fair value are classified and disclosed in one of the following hierarchy:

 

Level 1 -

Quoted prices are available in active markets for identical investments as of the period reporting date.

Level 2 -

Pricing inputs are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date, and fair value is determined through the use of models or other valuation methodologies.

Level 3 -

Pricing inputs are unobservable for the investment and included situations where there is little, if any, market activity for the investment.  The inputs into the determination of fair value require significant management judgment or estimation.

 

In the Company’s financial statements Fair Value is carrying amount.

 

Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the accompanying financial statements.

 

3. Going Concern

 

The financial statements have been prepared assuming that the Company will continue as a going concern. The Company is currently a public reorganized shell corporation and has no current business activity with losses of $47,670 as of December 31, 2023. The Company’s ability to continue as a going concern is dependent on continued support from a related party. This gives rise to substantial doubt about the Company’s ability to continue as a going concern for a period of twelve months after the issuance of these financial statements.

 

4. Amount Due to a Related party

 

The Company relies on a related party to advance funds to fund its operating expenses.  As of December 31, 2023 and 2022, the amounts advanced of $424,590 and $381,920 respectively are interest-free, unsecured and are repayable upon demand.

 

In addition, the Chief Executive Officer, Chief Financial Officer and Director of the Company is also a director of the related party.

 

5. Preferred Stock/Common Stock

 

Series A preferred stock

 

The Company is authorized under its Articles of Incorporation to issue 10,000,000 shares of Series A preferred stock with a par value of $0.001 per share. Each share of the Company’s preferred stock provides the holder with the right to vote 1,000 votes on all matters submitted to a vote of the stockholders of the Company and is convertible into 1,000 shares of the Company’s common stock. The preferred stock is non-participating and carries no dividend.  The Company does not have any issued shares of the preferred stock as of December 31, 2023 and 2022.

 

Common Stock

 

The Company is authorized to issue 250,000,000 shares of common stock with a par value of $0.001 per share.  During the year ended December 31, 2023 and 2022, the Company did not issue any shares of common stock or warrants.

 

 
15

Table of Contents

 

6. Income Tax 

 

As of December 31, 2023, the Company had net operating loss carry forwards of approximately $1,023,500 that may be available to reduce future years’ taxable income through 2039. Future tax benefits which may arise as a result of these losses have not been recognized in these financial statements, as their realization is determined not likely to occur and accordingly, the Company has recorded a valuation allowance for the deferred tax asset relating to these tax loss carry-forwards. The valuation allowance decreased by approximately $1,000 to reflect state tax rate of 5.5%.

 

The provision for Federal income tax consists of the following for the years ended December 31, 2023 and December 31, 2022:

 

 

 

December 31,

 

 

December 31,

 

 

 

2023

 

 

2022

 

 

 

 

 

 

 

 

Federal income tax benefit attributable to:

 

 

 

 

 

 

Net loss

 

$(12,394)

 

$(8,450)

Change in tax estimates

 

 

-

 

 

 

-

 

Less: valuation allowance

 

 

12,394

 

 

 

8,450

 

 

 

 

 

 

 

 

 

 

Net provision for Federal income taxes

 

$-

 

 

$-

 

 

The cumulative tax effect at the expected rate of 21% for 2023 and 21% for 2022 of significant items comprising our net deferred tax amount is as follows as of December 31, 2023 and December 31, 2022:

 

 

 

December 31,

 

 

December 31,

 

 

 

2023

 

 

2022

 

Deferred tax asset attributable to:

 

 

 

 

 

 

Net operating loss carryover

 

$258,844

 

 

$246,450

 

Less: valuation allowance

 

 

(258,844)

 

 

(246,450)

 

 

 

 

 

 

 

 

 

Net deferred tax asset

 

$-

 

 

$-

 

                                                                                                                                        

Due to the change in ownership in March 2012, the net operating loss carry forwards as of December 31, 2011 of $213,844 may be subject to limitations in accordance with Sec 382 of the provisions of the Tax Reform Act of 1986 for Federal income tax purposes. Tax return for the years ended December 31, 2023, 2022, 2021 and 2020 remain open to and it by Federal and State Tax Authorities.

 

 
16

Table of Contents

 

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

 

None

 

ITEM 9A. CONTROLS AND PROCEDURES

 

Disclosure Control and Procedures

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in company reports filed or submitted under the Securities Exchange Act of 1934, or the “Exchange Act,” is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms.  Disclosure controls and procedures include without limitation, controls and procedures designed to ensure that information required to be disclosed in company reports filed or submitted under the Exchange Act is accumulated and communicated to management, including our chief executive officer as appropriate to allow timely decisions regarding disclosure.

 

The Company’s management, with the participation of the Company’s President and Chief Financial Officer, evaluated the effectiveness of the Company’s disclosure controls and procedures as of the financial year end.  Based upon their evaluation, the Company’s President and Chief Financial Officer concluded that the Company’s disclosure controls and procedures were effective and did not note any material weakness.

 

Management’s Report on Internal Control over Financial Reporting

Management is responsible for establishing and maintaining adequate “internal control over financial reporting” as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act.  Internal control over financial reporting refers to the process designed by, or under the supervision of, our Chief Executive Officer and Chief Financial Officer, effected by our Board of Directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles, and includes those policies and procedures that:

 

 

i.

pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets;

 

 

 

 

ii.

provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures are being made only in accordance with authorizations of our management and directors; and

 

 

 

 

iii.

provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on our financial statements.

 

As of December 31, 2023, and as reported in the Registrant’s Form 10-K filing, management used the framework set forth in the report entitled “Internal Control – Integrated Framework” published by the Committee of Sponsoring Organizations of the Treadway Commission to evaluate the effectiveness of our internal control over financial reporting.  Based on its evaluation, management concluded that at December 31, 2023 there were no material weakness and concluded that the internal control over financial reporting was effective.  A material weakness is a deficiency, or a combination of control deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis.

 

During the year, there has been no change in our internal control over financial reporting that has materially affected or is reasonably likely to materially affect, our internal control over financial reporting.

 

ITEM 9B. OTHER INFORMATION

 

None

 

 
17

Table of Contents

 

PART III

 

ITEM 10.  DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

 

Generally, each of our directors is elected to a term of one year and serves until his or her successor is elected and qualified. The Directors and Officers of the Company are as follows:

 

Name

 

Age

 

Position

 

Term

Jordan Weingarten

 

34

 

President and Director

 

March 2012 to present

  

Mr. Weingarten graduated from York University with a degree in business administration. He is an executive with experience in financial controls, finance and global management. Amongst other assignments, Mr. Weingarten was financial control specialist at Trade Finance Solutions, Inc, a Canadian corporation, and was also involved in management at a global Polaroid Licensee. Mr. Weingarten also worked with international wholesalers and distributors of electronics and various other products. Based in Miami, Florida, Mr. Weingarten brings knowledge and experience of global economics, finances and cultural environment.  The President & Director of Green Planet Bioengineering Co. Ltd. is also a Director of the Related Party.

 

All of our directors hold offices until the next annual meeting of the stockholders of the Company, and until their successors have been qualified after being elected or appointed.  Officers serve at the discretion of the Board of Directors.

 

Director Compensation

We do not currently nor have we ever compensated our directors.

 

Involvement in Legal Proceedings

None of our executive officers or directors have been the subject of any order, judgment, or decree of any court of competent jurisdiction, or any regulatory agency permanently or temporarily enjoining, barring suspending or otherwise limiting him from acting as an investment advisor, underwriter, broker or dealer in the securities industry, or as an affiliated person, director or employee of an investment company, bank, savings and loan association, or insurance company, or from engaging in or continuing any conduct or practice in connection with any such activity or in connection with the purchase or sale of any securities.

 

None of our executive officers or directors has been convicted in any criminal proceeding (excluding traffic violations) or is the subject of a criminal proceeding that is currently pending.

 

None of our executive officers or directors is the subject of any material pending legal proceeding.

 

Audit Committee

The Company has not as of yet established an audit committee. The Board of Directors currently serves as the Company’s audit committee.

 

Compensation Committee

The Company has not as of yet established a compensation committee. The Board of Directors currently serves as the Company’s compensation committee.

 

Section 16 (A) Beneficial Ownership Reporting Compliance

Section 16 (A) of the Securities Exchange Act of 1934, as amended, requires the Company’s directors, executive officers and persons who own more than 10% of a class of the Company’s equity securities which are registered under the Exchange Act to file with the Securities and Exchange Commission initial reports of ownership and reports of changes of ownership of such registered securities. Such executive officers, directors and greater than 10% beneficial owners are required by Commission regulation to furnish the Company with copies of all Section 16 (A) forms filed by such reporting persons.

 

To the Company’s knowledge, based solely on a review of the copies of such reports furnished to the Company and on representations that no other reports were required, no person required to file such a report, failed to file during fiscal 2023 and 2022.

 

Code of Ethics

The Board of Directors adopted a Code of Ethics in April 2009, meeting the requirements of Section 406 of the Sarbanes-Oxley Act of 2002. The Company will provide to any person without charge, upon request, a copy of such Code of Ethics.

 

 
18

Table of Contents

 

ITEM 11. EXECUTIVE COMPENSATION

 

The Company did not pay any compensation to its executive officers for the years ended December 31, 2011 to 2023.

 

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

 

 

 

Shares of Common Stock 

 

 

 

 Beneficially Owned (1)

 

Name of Beneficial Owner

 

Number

 

 

% (2)

 

Global Funds Holdings Corp

 

 

18,508,733

 

 

 

92

 

                                                                                  

(1)

Beneficial ownership is determined in accordance with the rules of the SEC and generally includes voting or investment power with respect to securities. Shares of common stock subject to securities anticipated to be exercisable or convertible at or within 60 days of the date hereof, are deemed outstanding for computing the percentage of the person holding such option or warrant but are not deemed outstanding for computing the percentage of any other person. The indication herein that shares are anticipated to be beneficially owned is not an admission on the part of the listed stockholder that he, she or it is or will be a direct or indirect beneficial owner of those shares.

 

 

(2)

Based upon 20,006,402 shares of common stock issued and outstanding as of December 31, 2023.

 

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

 

Certain Relationships

None

 

Related Transactions

All related transactions have been reported in Part II Item 8 Financial Statements.

 

ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES

 

Audit Fees

The aggregate fees billed for fiscal year ended December 31, 2023 and 2022 for professional services rendered for the audit of the Company’s annual financial statements by Assurance Dimensions was $10,500 and by Liggett and Webb P.A. was $750  respectively

 

The aggregate fees billed for fiscal year ended December 31, 2023 and 2022 for professional services rendered for the reviews of the Company’s quarterly financial statements included in the Company’s Form 10-Q’s by Assurance Dimensions was $10,500 and by Liggett and Webb P.A. was $13,041 respectively.

 

Audit Related Fees

None

 

Tax Fees

Tax fees are those fees billed for professional services rendered for tax compliance, including preparation of corporate federal and state income tax returns, tax advice and tax planning. For the years ended December 31, 2023 and 2022, no tax fees were billed by Assurance Dimensions and Liggett & Webb, P.A.

 

All Other Fees

None

 

Policy for Pre-Approval of Audit and Non-Audit Services

 

We have not established an audit committee. Our board of directors approved the services rendered and fees charged by our independent registered public accounting firm.

 

Our board of directors’ policy is to pre-approve all audit services and all non-audit services that our independent registered public accounting firm is permitted to perform for us under applicable federal securities regulations. As permitted by the applicable regulations, our board of directors’ policy utilizes a combination of specific pre-approval on a case-by-case basis of individual engagements of the independent registered public accounting firm.

 

All engagements of the independent registered public accounting firm to perform any audit services and non-audit services since that date have been pre-approved by our board of directors in accordance with the pre-approval policy. The policy has not been waived in any instance. All engagements of the independent registered public accounting firm to perform any audit services and non-audit services prior to the date the pre-approval policy was implemented were approved by our board of directors in accordance with its normal functions.

.

 
19

Table of Contents

   

ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

 

(a) Exhibits

 

31.1

Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2

Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32

Certification pursuant to 18 U.S.C. Section 1350

 

 
20

Table of Contents

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned; thereunto duly authorized this 29th day of March, 2024.

 

 Green Planet Bioengineering Co., Ltd
    
By:/s/ Jordan Weingarten

 

 

Jordan Weingarten 
  President (Principal Executive Officer  
  and Principal Financial and Accounting Officer) and Director 

  

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

 

Date:  March 29, 2024 By:/s/ Jordan Weingarten

 

 

Jordan Weingarten 
  President and Director 

 

 
21

 

EX-31.1 2 gplb_ex311.htm EX-31.1 gplb_ex311.htm

 

EXHIBIT 31.1

 

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Jordan Weingarten, certify that:

 

1.

I have reviewed this Annual Report on Form 10-K of Green Planet Bioengineering Co., Ltd;

 

 

2.

Based on my knowledge, this Annual Report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this Annual Report;

 

 

3.

Based on my knowledge, the financial statements, and other financial information included in this Annual Report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this Annual Report;

 

 

4.

The registrants other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and we have:

 

 

a.

designed such disclosure controls and procedures, or have caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this Annual Report is being prepared;

 

 

 

 

b.

designed such internal controls over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

 

 

 

c.

evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this Annual Report our conclusions about the effectiveness of the disclosure controls and procedures, as of the period covered by this report based on such evaluation; and

 

 

 

 

d.

disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting ; and

 

5.

The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent function):

 

 

a.

all significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process summarize and report financial information; and

 

 

 

 

b.

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.

 

DATE: March 29, 2024 By: /s/ Jordan Weingarten

 

 

Jordan Weingarten  
   

President (Principal Executive Officer)

 

 

EX-31.2 3 gplb_ex312.htm EX-31.2 gplb_ex312.htm

 

EXHIBIT 31.2

 

CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Jordan Weingarten, certify that:

 

1.

I have reviewed this Annual Report on Form 10-K of Green Planet Bioengineering Co., Ltd;

 

 

2.

Based on my knowledge, this Annual Report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this Annual Report;

 

 

3.

Based on my knowledge, the financial statements, and other financial information included in this Annual Report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this Annual Report;

 

 

4.

The registrants other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and we have:

 

 

a.

designed such disclosure controls and procedures, or have caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this Annual Report is being prepared;

 

 

 

 

b.

designed such internal controls over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

 

 

 

c.

evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this Annual Report our conclusions about the effectiveness of the disclosure controls and procedures, as of the period covered by this report based on such evaluation; and

 

 

 

 

d.

disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting ; and

 

5.

The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent function):

 

 

a.

all significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process summarize and report financial information; and

 

 

 

 

b.

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.

 

DATE:   March 29, 2024 By: /s/ Jordan Weingarten

 

 

Jordan Weingarten  
    Chief Financial  
     Officer (Principal Financial and Accounting Officer)  

 

EX-32 4 gplb_ex32.htm EX-32 gplb_ex32.htm

 

EXHIBIT 32

 

CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C.

SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF

THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Annual Report of Green Planet Bioengineering Co., Ltd (the “Company”) on Form 10-K for the year ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Jordan Weingarten, President and Chief Financial Officer of the Company, certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and to the best of my knowledge and belief, that:

 

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (16 U.S.C. 78m or 78o (d); and

 

 

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

DATE:  March 29, 2024 By: /s/ Jordan Weingarten

 

 

Jordan Weingarten  
    President and Chief Financial  
    Officer (Principal Executive  

 

 

Officer and Principal Financial and Accounting Officer)

 

 

EX-101.SCH 5 gplb-20231231.xsd XBRL TAXONOMY EXTENSION SCHEMA 000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 000002 - Statement - Balance Sheets link:presentationLink link:calculationLink link:definitionLink 000003 - Statement - Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 000004 - Statement - Statements of Operations link:presentationLink link:calculationLink link:definitionLink 000005 - Statement - Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 000006 - Statement - Statements of Changes in Stockholders Deficit link:presentationLink link:calculationLink link:definitionLink 000007 - Disclosure - General Information link:presentationLink link:calculationLink link:definitionLink 000008 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 000009 - Disclosure - Going Concern link:presentationLink link:calculationLink link:definitionLink 000010 - Disclosure - Amount Due to a Related Company link:presentationLink link:calculationLink link:definitionLink 000011 - Disclosure - Preferred StockCommon Stock link:presentationLink link:calculationLink link:definitionLink 000012 - Disclosure - Income Tax link:presentationLink link:calculationLink link:definitionLink 000013 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 000014 - Disclosure - Income Tax (Tables) link:presentationLink link:calculationLink link:definitionLink 000015 - Disclosure - Going Concern (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000016 - Disclosure - Amount Due to a Related Party (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000017 - Disclosure - Preferred StockCommon Stock (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000018 - Disclosure - Income Tax (Details) link:presentationLink link:calculationLink link:definitionLink 000019 - Disclosure - Income Tax (Details 1) link:presentationLink link:calculationLink link:definitionLink 000020 - Disclosure - Income Tax (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 6 gplb-20231231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Entity Registrant Name Entity Central Index Key Document Type Amendment Flag Entity Voluntary Filers Current Fiscal Year End Date Entity Well Known Seasoned Issuer Entity Small Business Entity Shell Company Entity Emerging Growth Company Entity Current Reporting Status Document Period End Date Entity Filer Category Document Fiscal Period Focus Document Fiscal Year Focus Entity Common Stock Shares Outstanding Entity Public Float Document Annual Report Document Transition Report Document Fin Stmt Error Correction Flag Entity File Number Entity Incorporation State Country Code Entity Tax Identification Number Entity Address Address Line 1 Entity Address Address Line 2 Entity Address City Or Town Entity Address State Or Province Entity Address Postal Zip Code City Area Code Local Phone Number Entity Interactive Data Current Auditor Name Auditor Location Auditor Firm Id Balance Sheets ASSETS Current assets Cash TOTAL CURRENT ASSETS [Assets, Current] LIABILITIES AND STOCKHOLDERS DEFICIT LIABILITIES Current liabilities Accounts payable and accrued liabilities Amount due to a related party TOTAL CURRENT LIABILITIES [Liabilities, Current] STOCKHOLDERS DEFICIT Preferred stock : par value of $0.001 per share, Authorized: 10,000,000 shares at December 31, 2023 and December 31, 2022 Issued and outstanding : 0 shares at December 31, 2023 and December 31, 2022 Common stock : par value $0.001 per share Authorized : 250,000,000 shares at December 31, 2023 and December 31, 2022 Issued and outstanding : 20,006,402 shares at December 31, 2023 and December 31, 2022 Additional paid-in capital Accumulated deficit TOTAL STOCKHOLDERS DEFICIT [Stockholders' Equity Attributable to Parent] TOTAL LIABILITIES AND STOCKHOLDERS DEFICIT [Liabilities and Equity] Preferred Stock, Par Value Preferred Stock, Authorized Preferred Stock, Issued Preferred Stock, Outstanding Common Stock, Par Value Common Stock, Authorized Common Stock, Issued Common Stock, Outstanding Statements of Operations Administrative expenses [General and Administrative Expense] Interest expenses [Interest Expense] Loss before income taxes [Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest] Provision for income taxes Net loss [Net Income (Loss) Attributable to Parent] Loss per share -Basic and diluted Weighted average number of shares outstanding -Basic and diluted [-Basic and diluted] Statements of Cash Flows Cash flows from operating activities Net loss [Net Income (Loss), Including Portion Attributable to Noncontrolling Interest] Changes in operating assets and liabilities : Accounts payable and accrued liabilities [Increase (Decrease) in Accounts Payable and Accrued Liabilities] Net cash flows used by operating activities [Net Cash Provided by (Used in) Operating Activities] Cash flows from investing activities Cash flows from financing activities Amount due to a related company Net cash flows provided by financing activities [Net Cash Provided by (Used in) Financing Activities] Net change in cash [Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect] Cash - beginning of period Cash - end of period Supplemental disclosures for cash flow information: Cash paid for interest Cash paid for income taxes Statements of Changes in Stockholders Deficit Statement [Table] Statement [Line Items] Equity Components [Axis] Common Stock Preferred Stock Additional Paid-In Capital Accumulated Deficit Balance, shares [Shares, Issued] Balance, amount Net loss Balance, shares Balance, amount General Information General Information Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Summary of Significant Accounting Policies Summary Of Significant Accounting Policies Going Concern Going Concern Substantial Doubt about Going Concern [Text Block] Amount Due to a Related Company Amount Due to a Related Company Related Party Transactions Disclosure [Text Block] Preferred StockCommon Stock Preferred Stock/Common Stock Income Tax Income Tax Income Tax Disclosure [Text Block] Basis Of Presentation Use Of Estimates Cash And Cash Equivalents Income Taxes Loss Per Share Fair Value Measurements Schedule of Provision for income taxes Schedule of Deferred tax assets Net loss Amount Due to a Related Party (Details Narrative) Amount due to related party Preferred stock, par value Preferred stock, authorized Common stock, par value Common stock, authorized Voting rights shares Preferred stock convertible into shares Federal income tax benefit attributable to: Net loss [Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount] Change in tax estimates Less: valuation allowance Net provision for Federal income taxes Deferred tax asset attributable to: Net operating loss carryforwards Less: valuation allowance [Deferred Tax Assets, Valuation Allowance] Net deferred tax asset Net operating loss carry forwards Description of asset and allowances Cumulative tax effect rate EX-101.CAL 7 gplb-20231231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.PRE 8 gplb-20231231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EX-101.DEF 9 gplb-20231231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE GRAPHIC 10 gplb_10kimg7.jpg begin 644 gplb_10kimg7.jpg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end XML 12 R1.htm IDEA: XBRL DOCUMENT v3.24.1
Cover - USD ($)
12 Months Ended
Dec. 31, 2023
Mar. 29, 2024
Jun. 30, 2023
Cover [Abstract]      
Entity Registrant Name GREEN PLANET BIOENGINEERING CO., LTD.    
Entity Central Index Key 0001392449    
Document Type 10-K    
Amendment Flag false    
Entity Voluntary Filers No    
Current Fiscal Year End Date --12-31    
Entity Well Known Seasoned Issuer No    
Entity Small Business true    
Entity Shell Company true    
Entity Emerging Growth Company false    
Entity Current Reporting Status Yes    
Document Period End Date Dec. 31, 2023    
Entity Filer Category Non-accelerated Filer    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2023    
Entity Common Stock Shares Outstanding   20,006,402  
Entity Public Float     $ 722,205
Document Annual Report true    
Document Transition Report false    
Document Fin Stmt Error Correction Flag false    
Entity File Number 000-52622    
Entity Incorporation State Country Code DE    
Entity Tax Identification Number 37-1532842    
Entity Address Address Line 1 20807 Biscayne Blvd.    
Entity Address Address Line 2 Suite 203    
Entity Address City Or Town Aventura    
Entity Address State Or Province FL    
Entity Address Postal Zip Code 33180    
City Area Code 786    
Local Phone Number 279-2900    
Entity Interactive Data Current Yes    
Auditor Name Assurance Dimensions    
Auditor Location Margate, Florida    
Auditor Firm Id 5036    
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.24.1
Balance Sheets - USD ($)
Dec. 31, 2023
Dec. 31, 2022
Current assets    
Cash $ 0 $ 0
TOTAL CURRENT ASSETS 0 0
Current liabilities    
Accounts payable and accrued liabilities 5,000 0
Amount due to a related party 424,590 381,920
TOTAL CURRENT LIABILITIES 429,590 381,920
STOCKHOLDERS DEFICIT    
Preferred stock : par value of $0.001 per share, Authorized: 10,000,000 shares at December 31, 2023 and December 31, 2022 Issued and outstanding : 0 shares at December 31, 2023 and December 31, 2022 0 0
Common stock : par value $0.001 per share Authorized : 250,000,000 shares at December 31, 2023 and December 31, 2022 Issued and outstanding : 20,006,402 shares at December 31, 2023 and December 31, 2022 20,006 20,006
Additional paid-in capital 609,614 609,614
Accumulated deficit (1,059,210) (1,011,540)
TOTAL STOCKHOLDERS DEFICIT (429,590) (381,920)
TOTAL LIABILITIES AND STOCKHOLDERS DEFICIT $ 0 $ 0
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.24.1
Balance Sheets (Parenthetical) - $ / shares
Dec. 31, 2023
Dec. 31, 2022
Balance Sheets    
Preferred Stock, Par Value $ 0.001 $ 0.001
Preferred Stock, Authorized 10,000,000 10,000,000
Preferred Stock, Issued 0 0
Preferred Stock, Outstanding 0 0
Common Stock, Par Value $ 0.001 $ 0.001
Common Stock, Authorized 250,000,000 250,000,000
Common Stock, Issued 20,006,402 20,006,402
Common Stock, Outstanding 20,006,402 20,006,402
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.24.1
Statements of Operations - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Statements of Operations    
Administrative expenses $ (47,370) $ (32,533)
Interest expenses (300) 0
Loss before income taxes (47,670) (32,533)
Provision for income taxes 0 0
Net loss $ (47,670) $ (32,533)
Weighted average number of shares outstanding    
-Basic and diluted 20,006,402 20,006,402
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.24.1
Statements of Cash Flows - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Cash flows from operating activities    
Net loss $ (47,670) $ (32,533)
Changes in operating assets and liabilities :    
Accounts payable and accrued liabilities 5,000 0
Net cash flows used by operating activities (42,670) (32,533)
Cash flows from investing activities 0 0
Cash flows from financing activities    
Amount due to a related company 42,670 32,533
Net cash flows provided by financing activities 42,670 32,533
Net change in cash 0 0
Cash - beginning of period 0 0
Cash - end of period 0 0
Supplemental disclosures for cash flow information:    
Cash paid for interest 300 0
Cash paid for income taxes $ 0 $ 0
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.24.1
Statements of Changes in Stockholders Deficit - USD ($)
Total
Common Stock
Preferred Stock
Additional Paid-In Capital
Accumulated Deficit
Balance, shares at Dec. 31, 2021   20,006,402      
Balance, amount at Dec. 31, 2021 $ (349,387) $ 20,006 $ 0 $ 609,614 $ (979,007)
Net loss (32,533) $ 0 0 0 (32,533)
Balance, shares at Dec. 31, 2022   20,006,402      
Balance, amount at Dec. 31, 2022 (381,920) $ 20,006   609,614 (1,011,540)
Net loss (47,670) $ 0 $ 0 0 (47,670)
Balance, shares at Dec. 31, 2023   20,006,402      
Balance, amount at Dec. 31, 2023 $ (429,590) $ 20,006   $ 609,614 $ (1,059,210)
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.24.1
General Information
12 Months Ended
Dec. 31, 2023
General Information  
General Information

1. General Information

 

Mondo Acquisition II, Inc. was incorporated in the State of Delaware on October 30, 2006 and the name was changed to Green Planet Bioengineering Co., Ltd. (“Company”) on October 2, 2008. In October 2008, the Company acquired Elevated Throne Overseas Ltd, incorporated in British Virgin Islands, and its subsidiaries (“Elevated Throne”) and operated the business in the agritech sector in the People’s Republic of China. The Company divested Elevated Throne to One Bio, Corp. (“ONE”) on April 14, 2010. 

 

In March 2012, Global Funds Holdings Corp. (“Global Funds”) an Ontario, Canada corporation became a majority stockholder of the Company.

 

The Company operates as a public reorganized shell corporation with the purpose to acquire or merge with an existing business operation.   The Company's activities are subject to significant risks and uncertainties, as their ability to implement and execute future business plans and generate sufficient business revenue is directly influenced by their ability to secure adequate financing or find profitable business opportunities. 

XML 19 R8.htm IDEA: XBRL DOCUMENT v3.24.1
Summary of Significant Accounting Policies
12 Months Ended
Dec. 31, 2023
Summary of Significant Accounting Policies  
Summary Of Significant Accounting Policies

2. Summary of Significant Accounting Policies

 

Basis of Presentation

The financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”).

 

Use of Estimates

The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses for the years reported.  Actual results could differ from those estimates.  Significant items that require estimates were accruals of liabilities.

 

Cash and Cash Equivalents

Cash and cash equivalents include all cash, deposits in banks and other highly liquid investments with initial maturities of three months or less to be cash equivalents.  Balances of cash and cash equivalents in financial institutions does not exceed the government-insured limits as of December 31, 2023.

 

Income Taxes

The Company accounts for income taxes in accordance with FASB ASC Topic 740 “Income Taxes” under which deferred tax assets and liabilities are determined based on temporary differences between accounting and tax bases of assets and liabilities and net operating loss and credit carry forwards, using enacted tax rates in effect for the year in which the differences are expected to reverse.  Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized.  A provision for income tax expense is recognized for income taxes payable for the current period, plus the net changes in deferred tax amounts.  Any interest and penalties are expensed in the year that the Notice of Assessment is received. The Company’s practice is to recognize interest and/or penalties related to income tax matters as interest expense.

 

U.S. GAAP provides guidance for how uncertain tax positions should be recognized, measured, presented and disclosed in the financial statements. U.S. GAAP requires the evaluation of tax positions taken or expected to be taken in the course of preparing the Company’s tax returns to determine whether the tax positions are “more-likely-than-not” of being sustained by the applicable tax authority. Tax positions not deemed to meet a “more-likely-than-not” threshold would be recorded as a tax expense in the current year. The Company identifies its major tax jurisdictions as the U.S. for Federal tax purposes and Delaware for state tax purposes. The Company has concluded that there are no significant tax positions requiring recognition, measurement or disclosure in the financial statements for all open tax years. Tax years which are considered open by the relevant jurisdiction are subject to potential examination. 

 

Loss Per Share

Earnings per share is reported in accordance with FASB ASC Topic 260 “Earnings per Share” which requires dual presentation of basic earnings per share (“EPS”) and diluted EPS on the face of all statements of earnings, for all entities with complex capital structures.  Diluted EPS reflects the potential dilution that could occur from common shares issuable through the exercise or conversion of stock options, restricted stock awards, warrants and convertible securities. In certain circumstances, the conversion of these options, warrants and convertible securities are excluded from diluted EPS if the effect of such inclusion would be anti-dilutive.  Fully diluted EPS is not provided, when the effect is anti-dilutive. When the effect of dilution on loss per share is anti-dilutive, diluted loss per share equals the loss per share. As of December 31, 2023 and 2022 the Company does not have any common share equivalents outstanding.

Fair Value Measurements

FASB ASC Topic 820, “Fair Value Measurements and Disclosures” defines fair value, establishes a framework for measuring fair value in accordance with U.S. GAAP, and expands disclosures about fair value measurements. Investments measured and reported at fair value are classified and disclosed in one of the following hierarchy:

 

Level 1 -

Quoted prices are available in active markets for identical investments as of the period reporting date.

Level 2 -

Pricing inputs are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date, and fair value is determined through the use of models or other valuation methodologies.

Level 3 -

Pricing inputs are unobservable for the investment and included situations where there is little, if any, market activity for the investment.  The inputs into the determination of fair value require significant management judgment or estimation.

 

In the Company’s financial statements Fair Value is carrying amount.

 

Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the accompanying financial statements.

XML 20 R9.htm IDEA: XBRL DOCUMENT v3.24.1
Going Concern
12 Months Ended
Dec. 31, 2023
Going Concern  
Going Concern

3. Going Concern

 

The financial statements have been prepared assuming that the Company will continue as a going concern. The Company is currently a public reorganized shell corporation and has no current business activity with losses of $47,670 as of December 31, 2023. The Company’s ability to continue as a going concern is dependent on continued support from a related party. This gives rise to substantial doubt about the Company’s ability to continue as a going concern for a period of twelve months after the issuance of these financial statements.

XML 21 R10.htm IDEA: XBRL DOCUMENT v3.24.1
Amount Due to a Related Company
12 Months Ended
Dec. 31, 2023
Amount Due to a Related Company  
Amount Due to a Related Company

4. Amount Due to a Related party

 

The Company relies on a related party to advance funds to fund its operating expenses.  As of December 31, 2023 and 2022, the amounts advanced of $424,590 and $381,920 respectively are interest-free, unsecured and are repayable upon demand.

 

In addition, the Chief Executive Officer, Chief Financial Officer and Director of the Company is also a director of the related party.

XML 22 R11.htm IDEA: XBRL DOCUMENT v3.24.1
Preferred StockCommon Stock
12 Months Ended
Dec. 31, 2023
Preferred StockCommon Stock  
Preferred Stock/Common Stock

5. Preferred Stock/Common Stock

 

Series A preferred stock

 

The Company is authorized under its Articles of Incorporation to issue 10,000,000 shares of Series A preferred stock with a par value of $0.001 per share. Each share of the Company’s preferred stock provides the holder with the right to vote 1,000 votes on all matters submitted to a vote of the stockholders of the Company and is convertible into 1,000 shares of the Company’s common stock. The preferred stock is non-participating and carries no dividend.  The Company does not have any issued shares of the preferred stock as of December 31, 2023 and 2022.

 

Common Stock

 

The Company is authorized to issue 250,000,000 shares of common stock with a par value of $0.001 per share.  During the year ended December 31, 2023 and 2022, the Company did not issue any shares of common stock or warrants.

XML 23 R12.htm IDEA: XBRL DOCUMENT v3.24.1
Income Tax
12 Months Ended
Dec. 31, 2023
Income Tax  
Income Tax

6. Income Tax 

 

As of December 31, 2023, the Company had net operating loss carry forwards of approximately $1,023,500 that may be available to reduce future years’ taxable income through 2039. Future tax benefits which may arise as a result of these losses have not been recognized in these financial statements, as their realization is determined not likely to occur and accordingly, the Company has recorded a valuation allowance for the deferred tax asset relating to these tax loss carry-forwards. The valuation allowance decreased by approximately $1,000 to reflect state tax rate of 5.5%.

 

The provision for Federal income tax consists of the following for the years ended December 31, 2023 and December 31, 2022:

 

 

 

December 31,

 

 

December 31,

 

 

 

2023

 

 

2022

 

 

 

 

 

 

 

 

Federal income tax benefit attributable to:

 

 

 

 

 

 

Net loss

 

$(12,394)

 

$(8,450)

Change in tax estimates

 

 

-

 

 

 

-

 

Less: valuation allowance

 

 

12,394

 

 

 

8,450

 

 

 

 

 

 

 

 

 

 

Net provision for Federal income taxes

 

$-

 

 

$-

 

 

The cumulative tax effect at the expected rate of 21% for 2023 and 21% for 2022 of significant items comprising our net deferred tax amount is as follows as of December 31, 2023 and December 31, 2022:

 

 

 

December 31,

 

 

December 31,

 

 

 

2023

 

 

2022

 

Deferred tax asset attributable to:

 

 

 

 

 

 

Net operating loss carryover

 

$258,844

 

 

$246,450

 

Less: valuation allowance

 

 

(258,844)

 

 

(246,450)

 

 

 

 

 

 

 

 

 

Net deferred tax asset

 

$-

 

 

$-

 

                                                                                                                                        

Due to the change in ownership in March 2012, the net operating loss carry forwards as of December 31, 2011 of $213,844 may be subject to limitations in accordance with Sec 382 of the provisions of the Tax Reform Act of 1986 for Federal income tax purposes. Tax return for the years ended December 31, 2023, 2022, 2021 and 2020 remain open to and it by Federal and State Tax Authorities.

XML 24 R13.htm IDEA: XBRL DOCUMENT v3.24.1
Summary of Significant Accounting Policies (Policies)
12 Months Ended
Dec. 31, 2023
Summary of Significant Accounting Policies  
Basis Of Presentation

The financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”).

Use Of Estimates

The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses for the years reported.  Actual results could differ from those estimates.  Significant items that require estimates were accruals of liabilities.

Cash And Cash Equivalents

Cash and cash equivalents include all cash, deposits in banks and other highly liquid investments with initial maturities of three months or less to be cash equivalents.  Balances of cash and cash equivalents in financial institutions does not exceed the government-insured limits as of December 31, 2023.

Income Taxes

The Company accounts for income taxes in accordance with FASB ASC Topic 740 “Income Taxes” under which deferred tax assets and liabilities are determined based on temporary differences between accounting and tax bases of assets and liabilities and net operating loss and credit carry forwards, using enacted tax rates in effect for the year in which the differences are expected to reverse.  Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized.  A provision for income tax expense is recognized for income taxes payable for the current period, plus the net changes in deferred tax amounts.  Any interest and penalties are expensed in the year that the Notice of Assessment is received. The Company’s practice is to recognize interest and/or penalties related to income tax matters as interest expense.

 

U.S. GAAP provides guidance for how uncertain tax positions should be recognized, measured, presented and disclosed in the financial statements. U.S. GAAP requires the evaluation of tax positions taken or expected to be taken in the course of preparing the Company’s tax returns to determine whether the tax positions are “more-likely-than-not” of being sustained by the applicable tax authority. Tax positions not deemed to meet a “more-likely-than-not” threshold would be recorded as a tax expense in the current year. The Company identifies its major tax jurisdictions as the U.S. for Federal tax purposes and Delaware for state tax purposes. The Company has concluded that there are no significant tax positions requiring recognition, measurement or disclosure in the financial statements for all open tax years. Tax years which are considered open by the relevant jurisdiction are subject to potential examination. 

Loss Per Share

Earnings per share is reported in accordance with FASB ASC Topic 260 “Earnings per Share” which requires dual presentation of basic earnings per share (“EPS”) and diluted EPS on the face of all statements of earnings, for all entities with complex capital structures.  Diluted EPS reflects the potential dilution that could occur from common shares issuable through the exercise or conversion of stock options, restricted stock awards, warrants and convertible securities. In certain circumstances, the conversion of these options, warrants and convertible securities are excluded from diluted EPS if the effect of such inclusion would be anti-dilutive.  Fully diluted EPS is not provided, when the effect is anti-dilutive. When the effect of dilution on loss per share is anti-dilutive, diluted loss per share equals the loss per share. As of December 31, 2023 and 2022 the Company does not have any common share equivalents outstanding.

Fair Value Measurements

FASB ASC Topic 820, “Fair Value Measurements and Disclosures” defines fair value, establishes a framework for measuring fair value in accordance with U.S. GAAP, and expands disclosures about fair value measurements. Investments measured and reported at fair value are classified and disclosed in one of the following hierarchy:

 

Level 1 -

Quoted prices are available in active markets for identical investments as of the period reporting date.

Level 2 -

Pricing inputs are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date, and fair value is determined through the use of models or other valuation methodologies.

Level 3 -

Pricing inputs are unobservable for the investment and included situations where there is little, if any, market activity for the investment.  The inputs into the determination of fair value require significant management judgment or estimation.

 

In the Company’s financial statements Fair Value is carrying amount.

 

Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the accompanying financial statements.

XML 25 R14.htm IDEA: XBRL DOCUMENT v3.24.1
Income Tax (Tables)
12 Months Ended
Dec. 31, 2023
Income Tax  
Schedule of Provision for income taxes

 

 

December 31,

 

 

December 31,

 

 

 

2023

 

 

2022

 

 

 

 

 

 

 

 

Federal income tax benefit attributable to:

 

 

 

 

 

 

Net loss

 

$(12,394)

 

$(8,450)

Change in tax estimates

 

 

-

 

 

 

-

 

Less: valuation allowance

 

 

12,394

 

 

 

8,450

 

 

 

 

 

 

 

 

 

 

Net provision for Federal income taxes

 

$-

 

 

$-

 

Schedule of Deferred tax assets

 

 

December 31,

 

 

December 31,

 

 

 

2023

 

 

2022

 

Deferred tax asset attributable to:

 

 

 

 

 

 

Net operating loss carryover

 

$258,844

 

 

$246,450

 

Less: valuation allowance

 

 

(258,844)

 

 

(246,450)

 

 

 

 

 

 

 

 

 

Net deferred tax asset

 

$-

 

 

$-

 

XML 26 R15.htm IDEA: XBRL DOCUMENT v3.24.1
Going Concern (Details Narrative) - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Going Concern    
Net loss $ (47,670) $ (32,533)
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.24.1
Amount Due to a Related Party (Details Narrative) - USD ($)
Dec. 31, 2023
Dec. 31, 2022
Amount Due to a Related Party (Details Narrative)    
Amount due to related party $ 424,590 $ 381,920
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.24.1
Preferred StockCommon Stock (Details Narrative) - $ / shares
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Preferred StockCommon Stock    
Preferred stock, par value $ 0.001 $ 0.001
Preferred stock, authorized 10,000,000 10,000,000
Common stock, par value $ 0.001 $ 0.001
Common stock, authorized 250,000,000 250,000,000
Voting rights shares 1,000  
Preferred stock convertible into shares 1,000  
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.24.1
Income Tax (Details) - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Federal income tax benefit attributable to:    
Net loss $ (12,394) $ (8,450)
Change in tax estimates 0 0
Less: valuation allowance 12,394 8,450
Net provision for Federal income taxes $ 0 $ 0
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.24.1
Income Tax (Details 1) - USD ($)
Dec. 31, 2023
Dec. 31, 2022
Deferred tax asset attributable to:    
Net operating loss carryforwards $ 258,844 $ 246,450
Less: valuation allowance (258,844) (246,450)
Net deferred tax asset $ 0 $ 0
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.24.1
Income Tax (Details Narrative) - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2011
Income Tax      
Net operating loss carry forwards $ 1,023,500   $ 213,844
Description of asset and allowances The valuation allowance decreased by approximately $1,000 to reflect state tax rate of 5.5%    
Cumulative tax effect rate 21.00% 21.00%  
EXCEL 32 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 33 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 34 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 36 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1 html 26 95 1 false 4 0 false 4 false false R1.htm 000001 - Document - Cover Sheet http://greenplanetbio.com/role/Cover Cover Cover 1 false false R2.htm 000002 - Statement - Balance Sheets Sheet http://greenplanetbio.com/role/BalanceSheets Balance Sheets Statements 2 false false R3.htm 000003 - Statement - Balance Sheets (Parenthetical) Sheet http://greenplanetbio.com/role/BalanceSheetsParenthetical Balance Sheets (Parenthetical) Statements 3 false false R4.htm 000004 - Statement - Statements of Operations Sheet http://greenplanetbio.com/role/StatementsOfOperations Statements of Operations Statements 4 false false R5.htm 000005 - Statement - Statements of Cash Flows Sheet http://greenplanetbio.com/role/StatementsOfCashFlows Statements of Cash Flows Statements 5 false false R6.htm 000006 - Statement - Statements of Changes in Stockholders Deficit Sheet http://greenplanetbio.com/role/StatementsOfChangesInStockholdersDeficit Statements of Changes in Stockholders Deficit Statements 6 false false R7.htm 000007 - Disclosure - General Information Sheet http://greenplanetbio.com/role/GeneralInformation General Information Notes 7 false false R8.htm 000008 - Disclosure - Summary of Significant Accounting Policies Sheet http://greenplanetbio.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 000009 - Disclosure - Going Concern Sheet http://greenplanetbio.com/role/GoingConcern Going Concern Notes 9 false false R10.htm 000010 - Disclosure - Amount Due to a Related Company Sheet http://greenplanetbio.com/role/AmountDueToARelatedCompany Amount Due to a Related Company Notes 10 false false R11.htm 000011 - Disclosure - Preferred StockCommon Stock Sheet http://greenplanetbio.com/role/PreferredStockcommonStock Preferred StockCommon Stock Notes 11 false false R12.htm 000012 - Disclosure - Income Tax Sheet http://greenplanetbio.com/role/IncomeTax Income Tax Notes 12 false false R13.htm 000013 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://greenplanetbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://greenplanetbio.com/role/SummaryOfSignificantAccountingPolicies 13 false false R14.htm 000014 - Disclosure - Income Tax (Tables) Sheet http://greenplanetbio.com/role/IncomeTaxTables Income Tax (Tables) Tables http://greenplanetbio.com/role/IncomeTax 14 false false R15.htm 000015 - Disclosure - Going Concern (Details Narrative) Sheet http://greenplanetbio.com/role/GoingConcernDetailsNarrative Going Concern (Details Narrative) Details http://greenplanetbio.com/role/GoingConcern 15 false false R16.htm 000016 - Disclosure - Amount Due to a Related Party (Details Narrative) Sheet http://greenplanetbio.com/role/AmountDueToARelatedPartyDetailsNarrative Amount Due to a Related Party (Details Narrative) Details http://greenplanetbio.com/role/AmountDueToARelatedCompany 16 false false R17.htm 000017 - Disclosure - Preferred StockCommon Stock (Details Narrative) Sheet http://greenplanetbio.com/role/PreferredStockcommonStockDetailsNarrative Preferred StockCommon Stock (Details Narrative) Details http://greenplanetbio.com/role/PreferredStockcommonStock 17 false false R18.htm 000018 - Disclosure - Income Tax (Details) Sheet http://greenplanetbio.com/role/IncomeTaxDetails Income Tax (Details) Details http://greenplanetbio.com/role/IncomeTaxTables 18 false false R19.htm 000019 - Disclosure - Income Tax (Details 1) Sheet http://greenplanetbio.com/role/IncomeTaxDetails1 Income Tax (Details 1) Details http://greenplanetbio.com/role/IncomeTaxTables 19 false false R20.htm 000020 - Disclosure - Income Tax (Details Narrative) Sheet http://greenplanetbio.com/role/IncomeTaxDetailsNarrative Income Tax (Details Narrative) Details http://greenplanetbio.com/role/IncomeTaxTables 20 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 13 fact(s) appearing in ix:hidden were eligible for transformation: dei:CurrentFiscalYearEndDate, dei:DocumentFinStmtErrorCorrectionFlag, dei:EntityEmergingGrowthCompany, us-gaap:CommonStockParOrStatedValuePerShare, us-gaap:CommonStockSharesAuthorized, us-gaap:CommonStockSharesIssued, us-gaap:CommonStockSharesOutstanding, us-gaap:PreferredStockParOrStatedValuePerShare, us-gaap:PreferredStockSharesAuthorized, us-gaap:PreferredStockSharesIssued, us-gaap:PreferredStockSharesOutstanding - gplb_10k.htm 1 [DQC.US.0043.9873] The company has reported the concept ProfitLoss as part of the cash flow statement. This income item is being deducted from the value of operating cash flows in the calculation defined by the filer. This implies that the resulting operating cash flow calculation excludes this income item from cash flow from operations. If ProfitLoss represents income from discontinued operations then the element NetCashProvidedByUsedInOperatingActivitiesContinuingOperations should be used as the total rather than the current total element of NetCashProvidedByUsedInOperatingActivities. If the item is an income item and is being deducted because the value is negative then consider changing the sign and weight of the element. - https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd 4602, 9356 - https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd 4602, 9356 gplb-20231231.xsd gplb-20231231_cal.xml gplb-20231231_def.xml gplb-20231231_lab.xml gplb-20231231_pre.xml gplb_10k.htm gplb_10kimg7.jpg http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 39 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "gplb_10k.htm": { "nsprefix": "gplb", "nsuri": "http://greenplanetbio.com/20231231", "dts": { "schema": { "local": [ "gplb-20231231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] }, "calculationLink": { "local": [ "gplb-20231231_cal.xml" ] }, "definitionLink": { "local": [ "gplb-20231231_def.xml" ] }, "labelLink": { "local": [ "gplb-20231231_lab.xml" ] }, "presentationLink": { "local": [ "gplb-20231231_pre.xml" ] }, "inline": { "local": [ "gplb_10k.htm" ] } }, "keyStandard": 90, "keyCustom": 5, "axisStandard": 1, "axisCustom": 0, "memberStandard": 4, "memberCustom": 0, "hidden": { "total": 17, "http://xbrl.sec.gov/dei/2023": 7, "http://fasb.org/us-gaap/2023": 10 }, "contextCount": 26, "entityCount": 1, "segmentCount": 4, "elementCount": 130, "unitCount": 4, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 132, "http://xbrl.sec.gov/dei/2023": 34 }, "report": { "R1": { "role": "http://greenplanetbio.com/role/Cover", "longName": "000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "strong", "p", "td", "tr", "tbody", "table", "body", "html" ], "reportCount": 1, "baseRef": "gplb_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "strong", "p", "td", "tr", "tbody", "table", "body", "html" ], "reportCount": 1, "baseRef": "gplb_10k.htm", "first": true, "unique": true } }, "R2": { "role": "http://greenplanetbio.com/role/BalanceSheets", "longName": "000002 - Statement - Balance Sheets", "shortName": "Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "reportCount": 1, "baseRef": "gplb_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:AssetsCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "reportCount": 1, "baseRef": "gplb_10k.htm", "unique": true } }, "R3": { "role": "http://greenplanetbio.com/role/BalanceSheetsParenthetical", "longName": "000003 - Statement - Balance Sheets (Parenthetical)", "shortName": "Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:PreferredStockTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "gplb_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:PreferredStockSharesIssued", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "tbody", "table", "body", "html" ], "reportCount": 1, "baseRef": "gplb_10k.htm", "unique": true } }, "R4": { "role": "http://greenplanetbio.com/role/StatementsOfOperations", "longName": "000004 - Statement - Statements of Operations", "shortName": "Statements of Operations", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:GeneralAndAdministrativeExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "reportCount": 1, "baseRef": "gplb_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:GeneralAndAdministrativeExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "reportCount": 1, "baseRef": "gplb_10k.htm", "first": true, "unique": true } }, "R5": { "role": "http://greenplanetbio.com/role/StatementsOfCashFlows", "longName": "000005 - Statement - Statements of Cash Flows", "shortName": "Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ProfitLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "reportCount": 1, "baseRef": "gplb_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ProfitLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "reportCount": 1, "baseRef": "gplb_10k.htm", "first": true, "unique": true } }, "R6": { "role": "http://greenplanetbio.com/role/StatementsOfChangesInStockholdersDeficit", "longName": "000006 - Statement - Statements of Changes in Stockholders Deficit", "shortName": "Statements of Changes in Stockholders Deficit", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "AsOf2021-12-31_us-gaap_CommonStockMember", "name": "us-gaap:SharesIssued", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "reportCount": 1, "baseRef": "gplb_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2021-12-31_us-gaap_CommonStockMember", "name": "us-gaap:SharesIssued", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "reportCount": 1, "baseRef": "gplb_10k.htm", "first": true, "unique": true } }, "R7": { "role": "http://greenplanetbio.com/role/GeneralInformation", "longName": "000007 - Disclosure - General Information", "shortName": "General Information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "gplb_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "gplb_10k.htm", "first": true, "unique": true } }, "R8": { "role": "http://greenplanetbio.com/role/SummaryOfSignificantAccountingPolicies", "longName": "000008 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "gplb_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "gplb_10k.htm", "first": true, "unique": true } }, "R9": { "role": "http://greenplanetbio.com/role/GoingConcern", "longName": "000009 - Disclosure - Going Concern", "shortName": "Going Concern", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "gplb_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "gplb_10k.htm", "first": true, "unique": true } }, "R10": { "role": "http://greenplanetbio.com/role/AmountDueToARelatedCompany", "longName": "000010 - Disclosure - Amount Due to a Related Company", "shortName": "Amount Due to a Related Company", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "gplb_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "gplb_10k.htm", "first": true, "unique": true } }, "R11": { "role": "http://greenplanetbio.com/role/PreferredStockcommonStock", "longName": "000011 - Disclosure - Preferred StockCommon Stock", "shortName": "Preferred StockCommon Stock", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:PreferredStockTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "gplb_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:PreferredStockTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "gplb_10k.htm", "first": true, "unique": true } }, "R12": { "role": "http://greenplanetbio.com/role/IncomeTax", "longName": "000012 - Disclosure - Income Tax", "shortName": "Income Tax", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "gplb_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "gplb_10k.htm", "first": true, "unique": true } }, "R13": { "role": "http://greenplanetbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "longName": "000013 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "13", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "gplb_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "gplb_10k.htm", "first": true, "unique": true } }, "R14": { "role": "http://greenplanetbio.com/role/IncomeTaxTables", "longName": "000014 - Disclosure - Income Tax (Tables)", "shortName": "Income Tax (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "14", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "gplb_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "gplb_10k.htm", "first": true, "unique": true } }, "R15": { "role": "http://greenplanetbio.com/role/GoingConcernDetailsNarrative", "longName": "000015 - Disclosure - Going Concern (Details Narrative)", "shortName": "Going Concern (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "15", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "reportCount": 1, "baseRef": "gplb_10k.htm", "first": true }, "uniqueAnchor": null }, "R16": { "role": "http://greenplanetbio.com/role/AmountDueToARelatedPartyDetailsNarrative", "longName": "000016 - Disclosure - Amount Due to a Related Party (Details Narrative)", "shortName": "Amount Due to a Related Party (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "16", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "gplb:DueToRelatedPartyCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "gplb_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "gplb:DueToRelatedPartyCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "gplb_10k.htm", "first": true, "unique": true } }, "R17": { "role": "http://greenplanetbio.com/role/PreferredStockcommonStockDetailsNarrative", "longName": "000017 - Disclosure - Preferred StockCommon Stock (Details Narrative)", "shortName": "Preferred StockCommon Stock (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "17", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:PreferredStockTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "gplb_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "gplb:VotingRightsShares", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "us-gaap:PreferredStockTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "gplb_10k.htm", "unique": true } }, "R18": { "role": "http://greenplanetbio.com/role/IncomeTaxDetails", "longName": "000018 - Disclosure - Income Tax (Details)", "shortName": "Income Tax (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "18", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "gplb_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "gplb_10k.htm", "first": true, "unique": true } }, "R19": { "role": "http://greenplanetbio.com/role/IncomeTaxDetails1", "longName": "000019 - Disclosure - Income Tax (Details 1)", "shortName": "Income Tax (Details 1)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "19", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "gplb_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "gplb_10k.htm", "first": true, "unique": true } }, "R20": { "role": "http://greenplanetbio.com/role/IncomeTaxDetailsNarrative", "longName": "000020 - Disclosure - Income Tax (Details Narrative)", "shortName": "Income Tax (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "20", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:OperatingLossCarryforwards", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "gplb_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:OperatingLossCarryforwards", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "gplb_10k.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://greenplanetbio.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://greenplanetbio.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts payable and accrued liabilities", "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": [ "r5" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://greenplanetbio.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://greenplanetbio.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Additional paid-in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r27", "r245", "r281" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://greenplanetbio.com/role/StatementsOfChangesInStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Additional Paid-In Capital", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r112", "r113", "r114", "r189", "r267", "r268", "r269", "r276", "r283" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://greenplanetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://greenplanetbio.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://greenplanetbio.com/role/BalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://greenplanetbio.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL CURRENT ASSETS", "label": "[Assets, Current]", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r58", "r60", "r75", "r97", "r100", "r101", "r102", "r103", "r104", "r105", "r106", "r107", "r108", "r136", "r140", "r150", "r245", "r271", "r272", "r278" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://greenplanetbio.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current assets" } } }, "auth_ref": [] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorFirmId", "presentation": [ "http://greenplanetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Auditor Firm Id", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r258", "r259", "r260" ] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorLocation", "presentation": [ "http://greenplanetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "auth_ref": [ "r258", "r259", "r260" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorName", "presentation": [ "http://greenplanetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "auth_ref": [ "r258", "r259", "r260" ] }, "gplb_BasicAndDilutedEarningPerShare": { "xbrltype": "perShareItemType", "nsuri": "http://greenplanetbio.com/20231231", "localname": "BasicAndDilutedEarningPerShare", "presentation": [ "http://greenplanetbio.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "-Basic and diluted" } } }, "auth_ref": [] }, "gplb_BasicAndDilutedWeightedAverageNumberOfShareOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://greenplanetbio.com/20231231", "localname": "BasicAndDilutedWeightedAverageNumberOfShareOutstanding", "presentation": [ "http://greenplanetbio.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "verboseLabel": "-Basic and diluted", "label": "[-Basic and diluted]" } } }, "auth_ref": [] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://greenplanetbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Basis Of Presentation", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://greenplanetbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Cash And Cash Equivalents", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r12" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://greenplanetbio.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://greenplanetbio.com/role/BalanceSheets", "http://greenplanetbio.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash", "periodStartLabel": "Cash - beginning of period", "periodEndLabel": "Cash - end of period", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r11", "r35", "r73" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://greenplanetbio.com/role/StatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://greenplanetbio.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net change in cash", "label": "[Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect]", "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r1", "r35" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://greenplanetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://greenplanetbio.com/role/StatementsOfChangesInStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Common Stock", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r246", "r247", "r248", "r250", "r251", "r252", "r253", "r267", "r268", "r276", "r280", "r283" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://greenplanetbio.com/role/BalanceSheetsParenthetical", "http://greenplanetbio.com/role/PreferredStockcommonStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common Stock, Par Value", "verboseLabel": "Common stock, par value", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r26" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://greenplanetbio.com/role/BalanceSheetsParenthetical", "http://greenplanetbio.com/role/PreferredStockcommonStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common Stock, Authorized", "verboseLabel": "Common stock, authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r26", "r197" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://greenplanetbio.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r26" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://greenplanetbio.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r3", "r26", "r197", "r214", "r283", "r284" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://greenplanetbio.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://greenplanetbio.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Common stock : par value $0.001 per share Authorized : 250,000,000 shares at December 31, 2023 and December 31, 2022 Issued and outstanding : 20,006,402 shares at December 31, 2023 and December 31, 2022", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r26", "r167", "r245" ] }, "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertiblePreferredStockSharesIssuedUponConversion", "presentation": [ "http://greenplanetbio.com/role/PreferredStockcommonStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock convertible into shares", "documentation": "Number of shares issued for each share of convertible preferred stock that is converted." } } }, "auth_ref": [ "r4", "r19", "r25", "r41", "r110" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "gplb_CumulativeTaxEffectRate": { "xbrltype": "percentItemType", "nsuri": "http://greenplanetbio.com/20231231", "localname": "CumulativeTaxEffectRate", "presentation": [ "http://greenplanetbio.com/role/IncomeTaxDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Cumulative tax effect rate" } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://greenplanetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsNet", "crdr": "debit", "presentation": [ "http://greenplanetbio.com/role/IncomeTaxDetails1" ], "lang": { "en-us": { "role": { "label": "Net deferred tax asset", "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r274" ] }, "us-gaap_DeferredTaxAssetsNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsNetAbstract", "presentation": [ "http://greenplanetbio.com/role/IncomeTaxDetails1" ], "lang": { "en-us": { "role": { "label": "Deferred tax asset attributable to:" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "crdr": "debit", "presentation": [ "http://greenplanetbio.com/role/IncomeTaxDetails1" ], "lang": { "en-us": { "role": { "label": "Net operating loss carryforwards", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards." } } }, "auth_ref": [ "r21", "r275" ] }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsValuationAllowance", "crdr": "credit", "presentation": [ "http://greenplanetbio.com/role/IncomeTaxDetails1" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: valuation allowance", "label": "[Deferred Tax Assets, Valuation Allowance]", "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": [ "r124" ] }, "gplb_DescriptionOfAseetAndAllowances": { "xbrltype": "stringItemType", "nsuri": "http://greenplanetbio.com/20231231", "localname": "DescriptionOfAseetAndAllowances", "presentation": [ "http://greenplanetbio.com/role/IncomeTaxDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Description of asset and allowances" } } }, "auth_ref": [] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://greenplanetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r258", "r259", "r260" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://greenplanetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fin Stmt Error Correction Flag", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r258", "r259", "r260", "r262" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://greenplanetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://greenplanetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://greenplanetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://greenplanetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r261" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://greenplanetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_DueToRelatedPartiesCurrentAndNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DueToRelatedPartiesCurrentAndNoncurrentAbstract", "lang": { "en-us": { "role": { "label": "Amount Due to a Related Company" } } }, "auth_ref": [] }, "gplb_DueToRelatedPartyCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://greenplanetbio.com/20231231", "localname": "DueToRelatedPartyCurrent", "crdr": "credit", "presentation": [ "http://greenplanetbio.com/role/AmountDueToARelatedPartyDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Amount due to related party" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "presentation": [ "http://greenplanetbio.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Loss per share" } } }, "auth_ref": [] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://greenplanetbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Loss Per Share", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r14", "r15" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://greenplanetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address Address Line 1", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://greenplanetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address Address Line 2", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://greenplanetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address City Or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://greenplanetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://greenplanetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address State Or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://greenplanetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r257" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://greenplanetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://greenplanetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://greenplanetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r257" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://greenplanetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://greenplanetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r257" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://greenplanetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://greenplanetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r263" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://greenplanetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://greenplanetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r257" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://greenplanetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r257" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://greenplanetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r257" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://greenplanetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r257" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://greenplanetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://greenplanetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well Known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r264" ] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://greenplanetbio.com/role/StatementsOfChangesInStockholdersDeficit" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r3", "r56", "r64", "r65", "r66", "r77", "r78", "r79", "r81", "r86", "r88", "r90", "r98", "r99", "r111", "r112", "r113", "r114", "r128", "r129", "r142", "r143", "r144", "r145", "r146", "r147", "r148", "r151", "r152", "r153", "r154", "r155", "r156", "r158", "r174", "r175", "r176", "r189", "r237" ] }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": [ "http://greenplanetbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurements", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": [] }, "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract", "presentation": [ "http://greenplanetbio.com/role/IncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Federal income tax benefit attributable to:" } } }, "auth_ref": [] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://greenplanetbio.com/role/StatementsOfOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://greenplanetbio.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "negatedLabel": "Administrative expenses", "label": "[General and Administrative Expense]", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r34", "r218" ] }, "gplb_GeneralInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://greenplanetbio.com/20231231", "localname": "GeneralInformationAbstract", "lang": { "en-us": { "role": { "label": "General Information" } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://greenplanetbio.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://greenplanetbio.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Loss before income taxes", "label": "[Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest]", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r0", "r32", "r47", "r91", "r94", "r95", "r96", "r165", "r170", "r242" ] }, "gplb_IncomeTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://greenplanetbio.com/20231231", "localname": "IncomeTaxAbstract", "lang": { "en-us": { "role": { "label": "Income Tax" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://greenplanetbio.com/role/IncomeTax" ], "lang": { "en-us": { "role": { "verboseLabel": "Income Tax", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r76", "r115", "r121", "r122", "r126", "r130", "r132", "r133", "r134", "r184" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://greenplanetbio.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://greenplanetbio.com/role/IncomeTaxDetails", "http://greenplanetbio.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Provision for income taxes", "verboseLabel": "Net provision for Federal income taxes", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r50", "r55", "r87", "r88", "r93", "r119", "r131", "r173" ] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://greenplanetbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Income Taxes", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r63", "r117", "r118", "r122", "r123", "r125", "r127", "r182" ] }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "crdr": "debit", "presentation": [ "http://greenplanetbio.com/role/IncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Less: valuation allowance", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets." } } }, "auth_ref": [ "r273" ] }, "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate", "crdr": "debit", "presentation": [ "http://greenplanetbio.com/role/IncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Change in tax estimates", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates." } } }, "auth_ref": [ "r116", "r120" ] }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "crdr": "debit", "presentation": [ "http://greenplanetbio.com/role/IncomeTaxDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Net loss", "label": "[Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount]", "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r120" ] }, "us-gaap_IncomeTaxesPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxesPaid", "crdr": "credit", "presentation": [ "http://greenplanetbio.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash paid for income taxes", "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income." } } }, "auth_ref": [ "r10", "r13" ] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://greenplanetbio.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://greenplanetbio.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Accounts payable and accrued liabilities", "label": "[Increase (Decrease) in Accounts Payable and Accrued Liabilities]", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": [ "r2" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://greenplanetbio.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities :" } } }, "auth_ref": [] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://greenplanetbio.com/role/StatementsOfOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://greenplanetbio.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest expenses", "label": "[Interest Expense]", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": [ "r22", "r49", "r67", "r92", "r157", "r222", "r254", "r282" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://greenplanetbio.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash paid for interest", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r68", "r71", "r72" ] }, "us-gaap_LiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAbstract", "presentation": [ "http://greenplanetbio.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "LIABILITIES" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://greenplanetbio.com/role/BalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://greenplanetbio.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS DEFICIT", "label": "[Liabilities and Equity]", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r31", "r46", "r169", "r245", "r266", "r270", "r277" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://greenplanetbio.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS DEFICIT" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://greenplanetbio.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://greenplanetbio.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL CURRENT LIABILITIES", "label": "[Liabilities, Current]", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r7", "r59", "r75", "r97", "r100", "r101", "r102", "r103", "r104", "r105", "r106", "r107", "r108", "r137", "r140", "r141", "r150", "r245", "r271", "r278", "r279" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://greenplanetbio.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current liabilities" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://greenplanetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://greenplanetbio.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://greenplanetbio.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash flows provided by financing activities", "label": "[Net Cash Provided by (Used in) Financing Activities]", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r70" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://greenplanetbio.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://greenplanetbio.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://greenplanetbio.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from investing activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r70" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://greenplanetbio.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://greenplanetbio.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash flows used by operating activities", "label": "[Net Cash Provided by (Used in) Operating Activities]", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r35", "r36", "r37" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://greenplanetbio.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://greenplanetbio.com/role/StatementsOfOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://greenplanetbio.com/role/GoingConcernDetailsNarrative", "http://greenplanetbio.com/role/StatementsOfChangesInStockholdersDeficit", "http://greenplanetbio.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "label": "[Net Income (Loss) Attributable to Parent]", "verboseLabel": "Net loss", "terseLabel": "Net loss", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r33", "r37", "r48", "r57", "r61", "r62", "r66", "r75", "r80", "r82", "r83", "r84", "r85", "r87", "r88", "r89", "r91", "r94", "r95", "r96", "r97", "r100", "r101", "r102", "r103", "r104", "r105", "r106", "r107", "r108", "r149", "r150", "r172", "r216", "r235", "r236", "r242", "r254", "r271" ] }, "us-gaap_OperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLossCarryforwards", "crdr": "debit", "presentation": [ "http://greenplanetbio.com/role/IncomeTaxDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Net operating loss carry forwards", "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [ "r20" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://greenplanetbio.com/role/GeneralInformation" ], "lang": { "en-us": { "role": { "verboseLabel": "General Information", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r23", "r45", "r179", "r180" ] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://greenplanetbio.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://greenplanetbio.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Amount due to a related party", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r6", "r245" ] }, "us-gaap_PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockMember", "presentation": [ "http://greenplanetbio.com/role/StatementsOfChangesInStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Preferred Stock", "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company." } } }, "auth_ref": [ "r246", "r247", "r250", "r251", "r252", "r253", "r280", "r283" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://greenplanetbio.com/role/BalanceSheetsParenthetical", "http://greenplanetbio.com/role/PreferredStockcommonStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Par Value", "verboseLabel": "Preferred stock, par value", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r25", "r109" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://greenplanetbio.com/role/BalanceSheetsParenthetical", "http://greenplanetbio.com/role/PreferredStockcommonStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Authorized", "verboseLabel": "Preferred stock, authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r25", "r197" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": [ "http://greenplanetbio.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Issued", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": [ "r25", "r109" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://greenplanetbio.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r25", "r197", "r214", "r283", "r284" ] }, "us-gaap_PreferredStockTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockTextBlock", "presentation": [ "http://greenplanetbio.com/role/PreferredStockcommonStock" ], "lang": { "en-us": { "role": { "label": "Preferred Stock/Common Stock", "documentation": "The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock." } } }, "auth_ref": [ "r40" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://greenplanetbio.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://greenplanetbio.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Preferred stock : par value of $0.001 per share, Authorized: 10,000,000 shares at December 31, 2023 and December 31, 2022 Issued and outstanding : 0 shares at December 31, 2023 and December 31, 2022", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r25", "r166", "r245" ] }, "gplb_PreferredStockcommonStockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://greenplanetbio.com/20231231", "localname": "PreferredStockcommonStockAbstract", "lang": { "en-us": { "role": { "label": "Preferred StockCommon Stock" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromRelatedPartyDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromRelatedPartyDebt", "crdr": "debit", "calculation": { "http://greenplanetbio.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://greenplanetbio.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Amount due to a related company", "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates." } } }, "auth_ref": [ "r9" ] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://greenplanetbio.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://greenplanetbio.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Net loss", "label": "[Net Income (Loss), Including Portion Attributable to Noncontrolling Interest]", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r57", "r61", "r62", "r69", "r75", "r80", "r87", "r88", "r91", "r94", "r95", "r96", "r97", "r100", "r101", "r102", "r103", "r104", "r105", "r106", "r107", "r108", "r135", "r138", "r139", "r149", "r150", "r165", "r171", "r188", "r216", "r235", "r236", "r242", "r243", "r244", "r255", "r265", "r271" ] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Amount Due to a Related Party (Details Narrative)" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://greenplanetbio.com/role/AmountDueToARelatedCompany" ], "lang": { "en-us": { "role": { "verboseLabel": "Amount Due to a Related Company", "label": "Related Party Transactions Disclosure [Text Block]", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r159", "r160", "r161", "r162", "r163", "r185", "r186", "r187", "r219", "r220", "r221", "r240", "r241" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://greenplanetbio.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://greenplanetbio.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r28", "r42", "r168", "r177", "r178", "r183", "r198", "r245" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://greenplanetbio.com/role/StatementsOfChangesInStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Accumulated Deficit", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r56", "r77", "r78", "r79", "r81", "r86", "r88", "r98", "r99", "r112", "r113", "r114", "r128", "r129", "r142", "r144", "r145", "r147", "r148", "r174", "r176", "r189", "r283" ] }, "us-gaap_RisksAndUncertaintiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RisksAndUncertaintiesAbstract", "lang": { "en-us": { "role": { "label": "Going Concern" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "presentation": [ "http://greenplanetbio.com/role/IncomeTaxTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Provision for income taxes", "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years." } } }, "auth_ref": [ "r44" ] }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": [ "http://greenplanetbio.com/role/IncomeTaxTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Deferred tax assets", "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets." } } }, "auth_ref": [ "r43" ] }, "us-gaap_SharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesIssued", "presentation": [ "http://greenplanetbio.com/role/StatementsOfChangesInStockholdersDeficit" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance, shares", "label": "[Shares, Issued]", "periodEndLabel": "Balance, shares", "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury." } } }, "auth_ref": [ "r3" ] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://greenplanetbio.com/role/SummaryOfSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "label": "Summary Of Significant Accounting Policies", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r38", "r74" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://greenplanetbio.com/role/StatementsOfChangesInStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r3", "r8", "r56", "r64", "r65", "r66", "r77", "r78", "r79", "r81", "r86", "r88", "r90", "r98", "r99", "r111", "r112", "r113", "r114", "r128", "r129", "r142", "r143", "r144", "r145", "r146", "r147", "r148", "r151", "r152", "r153", "r154", "r155", "r156", "r158", "r174", "r175", "r176", "r189", "r237" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://greenplanetbio.com/role/StatementsOfChangesInStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r77", "r78", "r79", "r90", "r164", "r181", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r215", "r217", "r218", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r237", "r249" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statements of Cash Flows" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Balance Sheets" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statements of Changes in Stockholders Deficit" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://greenplanetbio.com/role/StatementsOfChangesInStockholdersDeficit" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r77", "r78", "r79", "r90", "r164", "r181", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r215", "r217", "r218", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r237", "r249" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://greenplanetbio.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://greenplanetbio.com/role/BalanceSheets", "http://greenplanetbio.com/role/StatementsOfChangesInStockholdersDeficit" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL STOCKHOLDERS DEFICIT", "label": "[Stockholders' Equity Attributable to Parent]", "periodStartLabel": "Balance, amount", "periodEndLabel": "Balance, amount", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r26", "r29", "r30", "r39", "r199", "r214", "r238", "r239", "r245", "r256", "r266", "r270", "r277", "r283" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://greenplanetbio.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "STOCKHOLDERS DEFICIT" } } }, "auth_ref": [] }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "presentation": [ "http://greenplanetbio.com/role/GoingConcern" ], "lang": { "en-us": { "role": { "verboseLabel": "Going Concern", "label": "Substantial Doubt about Going Concern [Text Block]", "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern." } } }, "auth_ref": [ "r24" ] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://greenplanetbio.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Supplemental disclosures for cash flow information:" } } }, "auth_ref": [] }, "us-gaap_SupplementalIncomeStatementElementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalIncomeStatementElementsAbstract", "lang": { "en-us": { "role": { "label": "Statements of Operations" } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://greenplanetbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Use Of Estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r16", "r17", "r18", "r51", "r52", "r53", "r54" ] }, "gplb_VotingRightsShares": { "xbrltype": "sharesItemType", "nsuri": "http://greenplanetbio.com/20231231", "localname": "VotingRightsShares", "presentation": [ "http://greenplanetbio.com/role/PreferredStockcommonStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Voting rights shares" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": [ "http://greenplanetbio.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Weighted average number of shares outstanding" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19,20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "25", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "40", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205-40/tableOfContent" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "9", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//810/tableOfContent" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r50": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r51": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r52": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r53": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r54": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r55": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r56": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r57": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r58": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r59": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r60": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r61": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r62": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r63": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1" }, "r64": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r65": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r66": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r67": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(210.5-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r68": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r69": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2" }, "r70": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r71": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r72": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r73": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r74": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r75": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r76": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r77": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r78": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r79": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r80": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r81": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r82": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r83": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r84": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r85": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-15" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//850/tableOfContent" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r242": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r243": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r244": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K" }, "r245": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r246": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r247": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r248": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r249": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r250": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r251": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r252": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r253": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r254": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r255": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r256": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r257": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r258": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r259": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r260": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r261": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r262": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r263": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r264": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r265": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r266": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r267": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r268": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r269": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r270": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r271": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r272": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r273": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r274": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r275": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6" }, "r276": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r277": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r278": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r279": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r280": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r281": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r282": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r283": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r284": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" } } } ZIP 40 0001654954-24-003942-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001654954-24-003942-xbrl.zip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gplb_10k_htm.xml IDEA: XBRL DOCUMENT 0001392449 2023-01-01 2023-12-31 0001392449 2011-12-31 0001392449 us-gaap:RetainedEarningsMember 2023-12-31 0001392449 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001392449 us-gaap:CommonStockMember 2023-12-31 0001392449 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0001392449 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0001392449 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001392449 us-gaap:PreferredStockMember 2023-01-01 2023-12-31 0001392449 us-gaap:RetainedEarningsMember 2022-12-31 0001392449 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001392449 us-gaap:CommonStockMember 2022-12-31 0001392449 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001392449 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001392449 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001392449 us-gaap:PreferredStockMember 2022-01-01 2022-12-31 0001392449 us-gaap:RetainedEarningsMember 2021-12-31 0001392449 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001392449 us-gaap:CommonStockMember 2021-12-31 0001392449 us-gaap:PreferredStockMember 2021-12-31 0001392449 2021-12-31 0001392449 2022-01-01 2022-12-31 0001392449 2022-12-31 0001392449 2023-12-31 0001392449 2024-03-29 0001392449 2023-06-30 iso4217:USD shares iso4217:USD shares pure 0001392449 false --12-31 false FY 2023 false 0.001 10000000 0 0 0 0.001 250000000 20006402 20006402 20006402 10-K true 2023-12-31 false 000-52622 GREEN PLANET BIOENGINEERING CO., LTD. DE 37-1532842 20807 Biscayne Blvd. Suite 203 Aventura FL 33180 786 279-2900 No No Yes Yes Non-accelerated Filer true true 722205 20006402 5036 Assurance Dimensions Margate, Florida 0 0 0 0 5000 0 424590 381920 429590 381920 0.001 10000000 0 0 0 0.001 250000000 20006402 20006 20006 609614 609614 -1059210 -1011540 -429590 -381920 0 0 47370 32533 300 0 -47670 -32533 0 0 -47670 -32533 20006402 20006402 47670 32533 5000 0 -42670 -32533 0 0 42670 32533 42670 32533 0 0 0 0 0 0 300 0 0 0 0 20006402 20006 609614 -979007 -349387 0 0 0 -32533 -32533 20006402 20006 609614 -1011540 -381920 0 0 0 -47670 -47670 20006402 20006 609614 -1059210 -429590 <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>1. General Information</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Mondo Acquisition II, Inc. was incorporated in the State of Delaware on October 30, 2006 and the name was changed to Green Planet Bioengineering Co., Ltd. (“Company”) on October 2, 2008. In October 2008, the Company acquired Elevated Throne Overseas Ltd, incorporated in British Virgin Islands, and its subsidiaries (“Elevated Throne”) and operated the business in the agritech sector in the People’s Republic of China. The Company divested Elevated Throne to One Bio, Corp. (“ONE”) on April 14, 2010.  </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In March 2012, Global Funds Holdings Corp. (“Global Funds”) an Ontario, Canada corporation became a majority stockholder of the Company.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company operates as a public reorganized shell corporation with the purpose to acquire or merge with an existing business operation.   The Company's activities are subject to significant risks and uncertainties, as their ability to implement and execute future business plans and generate sufficient business revenue is directly influenced by their ability to secure adequate financing or find profitable business opportunities.  </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>2. Summary of Significant </strong><strong>Accounting Policies</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Basis of Presentation</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”). </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Use of Estimates</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses for the years reported.  Actual results could differ from those estimates.  Significant items that require estimates were accruals of liabilities.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Cash and Cash Equivalents</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Cash and cash equivalents include all cash, deposits in banks and other highly liquid investments with initial maturities of three months or less to be cash equivalents.  Balances of cash and cash equivalents in financial institutions does not exceed the government-insured limits as of December 31, 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Income Taxes</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company accounts for income taxes in accordance with FASB ASC Topic 740 “<em>Income Taxes</em>” under which deferred tax assets and liabilities are determined based on temporary differences between accounting and tax bases of assets and liabilities and net operating loss and credit carry forwards, using enacted tax rates in effect for the year in which the differences are expected to reverse.  Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized.  A provision for income tax expense is recognized for income taxes payable for the current period, plus the net changes in deferred tax amounts.  Any interest and penalties are expensed in the year that the Notice of Assessment is received. The Company’s practice is to recognize interest and/or penalties related to income tax matters as interest expense.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">U.S. GAAP provides guidance for how uncertain tax positions should be recognized, measured, presented and disclosed in the financial statements. U.S. GAAP requires the evaluation of tax positions taken or expected to be taken in the course of preparing the Company’s tax returns to determine whether the tax positions are “more-likely-than-not” of being sustained by the applicable tax authority. Tax positions not deemed to meet a “more-likely-than-not” threshold would be recorded as a tax expense in the current year. The Company identifies its major tax jurisdictions as the U.S. for Federal tax purposes and Delaware for state tax purposes. The Company has concluded that there are no significant tax positions requiring recognition, measurement or disclosure in the financial statements for all open tax years. Tax years which are considered open by the relevant jurisdiction are subject to potential examination. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Loss Per Share</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Earnings per share is reported in accordance with FASB ASC Topic 260 “<em>Earnings per Share</em>” which requires dual presentation of basic earnings per share (“EPS”) and diluted EPS on the face of all statements of earnings, for all entities with complex capital structures.  Diluted EPS reflects the potential dilution that could occur from common shares issuable through the exercise or conversion of stock options, restricted stock awards, warrants and convertible securities. In certain circumstances, the conversion of these options, warrants and convertible securities are excluded from diluted EPS if the effect of such inclusion would be anti-dilutive.  Fully diluted EPS is not provided, when the effect is anti-dilutive. When the effect of dilution on loss per share is anti-dilutive, diluted loss per share equals the loss per share. As of December 31, 2023 and 2022 the Company does not have any common share equivalents outstanding.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Fair Value Measurements</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">FASB ASC Topic 820, “<em>Fair Value Measurements and Disclosures</em>” defines fair value, establishes a framework for measuring fair value in accordance with U.S. GAAP, and expands disclosures about fair value measurements. Investments measured and reported at fair value are classified and disclosed in one of the following hierarchy:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;font-size:10pt;text-align:left;width:100%"><tbody><tr style="height:15px"><td style="width:8%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Level 1 -</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Quoted prices are available in active markets for identical investments as of the period reporting date.</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Level 2 -</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Pricing inputs are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date, and fair value is determined through the use of models or other valuation methodologies. </p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Level 3 -</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Pricing inputs are unobservable for the investment and included situations where there is little, if any, market activity for the investment.  The inputs into the determination of fair value require significant management judgment or estimation. </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In the Company’s financial statements Fair Value is carrying amount.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the accompanying financial statements.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”). </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses for the years reported.  Actual results could differ from those estimates.  Significant items that require estimates were accruals of liabilities.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Cash and cash equivalents include all cash, deposits in banks and other highly liquid investments with initial maturities of three months or less to be cash equivalents.  Balances of cash and cash equivalents in financial institutions does not exceed the government-insured limits as of December 31, 2023.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company accounts for income taxes in accordance with FASB ASC Topic 740 “<em>Income Taxes</em>” under which deferred tax assets and liabilities are determined based on temporary differences between accounting and tax bases of assets and liabilities and net operating loss and credit carry forwards, using enacted tax rates in effect for the year in which the differences are expected to reverse.  Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized.  A provision for income tax expense is recognized for income taxes payable for the current period, plus the net changes in deferred tax amounts.  Any interest and penalties are expensed in the year that the Notice of Assessment is received. The Company’s practice is to recognize interest and/or penalties related to income tax matters as interest expense.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">U.S. GAAP provides guidance for how uncertain tax positions should be recognized, measured, presented and disclosed in the financial statements. U.S. GAAP requires the evaluation of tax positions taken or expected to be taken in the course of preparing the Company’s tax returns to determine whether the tax positions are “more-likely-than-not” of being sustained by the applicable tax authority. Tax positions not deemed to meet a “more-likely-than-not” threshold would be recorded as a tax expense in the current year. The Company identifies its major tax jurisdictions as the U.S. for Federal tax purposes and Delaware for state tax purposes. The Company has concluded that there are no significant tax positions requiring recognition, measurement or disclosure in the financial statements for all open tax years. Tax years which are considered open by the relevant jurisdiction are subject to potential examination. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Earnings per share is reported in accordance with FASB ASC Topic 260 “<em>Earnings per Share</em>” which requires dual presentation of basic earnings per share (“EPS”) and diluted EPS on the face of all statements of earnings, for all entities with complex capital structures.  Diluted EPS reflects the potential dilution that could occur from common shares issuable through the exercise or conversion of stock options, restricted stock awards, warrants and convertible securities. In certain circumstances, the conversion of these options, warrants and convertible securities are excluded from diluted EPS if the effect of such inclusion would be anti-dilutive.  Fully diluted EPS is not provided, when the effect is anti-dilutive. When the effect of dilution on loss per share is anti-dilutive, diluted loss per share equals the loss per share. As of December 31, 2023 and 2022 the Company does not have any common share equivalents outstanding.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">FASB ASC Topic 820, “<em>Fair Value Measurements and Disclosures</em>” defines fair value, establishes a framework for measuring fair value in accordance with U.S. GAAP, and expands disclosures about fair value measurements. Investments measured and reported at fair value are classified and disclosed in one of the following hierarchy:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;font-size:10pt;text-align:left;width:100%"><tbody><tr style="height:15px"><td style="width:8%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Level 1 -</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Quoted prices are available in active markets for identical investments as of the period reporting date.</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Level 2 -</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Pricing inputs are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date, and fair value is determined through the use of models or other valuation methodologies. </p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Level 3 -</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Pricing inputs are unobservable for the investment and included situations where there is little, if any, market activity for the investment.  The inputs into the determination of fair value require significant management judgment or estimation. </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In the Company’s financial statements Fair Value is carrying amount.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the accompanying financial statements.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>3. Going Concern</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The financial statements have been prepared assuming that the Company will continue as a going concern. The Company is currently a public reorganized shell corporation and has no current business activity with losses of $47,670 as of December 31, 2023. The Company’s ability to continue as a going concern is dependent on continued support from a related party. This gives rise to substantial doubt about the Company’s ability to continue as a going concern for a period of twelve months after the issuance of these financial statements.</p> -47670 <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>4. Amount Due to a Related party</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company relies on a related party to advance funds to fund its operating expenses.  As of December 31, 2023 and 2022, the amounts advanced of $424,590 and $381,920 respectively are interest-free, unsecured and are repayable upon demand.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In addition, the Chief Executive Officer, Chief Financial Officer and Director of the Company is also a director of the related party.</p> 424590 381920 <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>5. Preferred Stock/Common Stock</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Series A preferred stock</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company is authorized under its Articles of Incorporation to issue 10,000,000 shares of Series A preferred stock with a par value of $0.001 per share. Each share of the Company’s preferred stock provides the holder with the right to vote 1,000 votes on all matters submitted to a vote of the stockholders of the Company and is convertible into 1,000 shares of the Company’s common stock. The preferred stock is non-participating and carries no dividend.  The Company does not have any issued shares of the preferred stock as of December 31, 2023 and 2022.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Common Stock</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company is authorized to issue 250,000,000 shares of common stock with a par value of $0.001 per share.  During the year ended December 31, 2023 and 2022, the Company did not issue any shares of common stock or warrants.</p> 10000000 0.001 1000 1000 250000000 0.001 <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>6. Income Tax  </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of December 31, 2023, the Company had net operating loss carry forwards of approximately $1,023,500 that may be available to reduce future years’ taxable income through 2039. Future tax benefits which may arise as a result of these losses have not been recognized in these financial statements, as their realization is determined not likely to occur and accordingly, the Company has recorded a valuation allowance for the deferred tax asset relating to these tax loss carry-forwards. The valuation allowance decreased by approximately $1,000 to reflect state tax rate of 5.5%.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The provision for Federal income tax consists of the following for the years ended December 31, 2023 and December 31, 2022:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">  </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:90%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>December 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>December 31, </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>2023 </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>2022</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Federal income tax benefit attributable to:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Net loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(12,394</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(8,450</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Change in tax estimates</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Less: valuation allowance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">12,394</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">8,450</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Net provision for Federal income taxes</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">  </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The cumulative tax effect at the expected rate of 21% for 2023 and 21% for 2022 of significant items comprising our net deferred tax amount is as follows as of December 31, 2023 and December 31, 2022:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:90%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>December 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>December 31, </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>2023</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>2022</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Deferred tax asset attributable to:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Net operating loss carryover</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">258,844</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">246,450</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Less: valuation allowance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(258,844</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(246,450</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Net deferred tax asset</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">                                                                                                                                         </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Due to the change in ownership in March 2012, the net operating loss carry forwards as of December 31, 2011 of $213,844 may be subject to limitations in accordance with Sec 382 of the provisions of the Tax Reform Act of 1986 for Federal income tax purposes. Tax return for the years ended December 31, 2023, 2022, 2021 and 2020 remain open to and it by Federal and State Tax Authorities.</p> 1023500 The valuation allowance decreased by approximately $1,000 to reflect state tax rate of 5.5% <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:90%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>December 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>December 31, </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>2023 </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>2022</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Federal income tax benefit attributable to:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Net loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(12,394</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(8,450</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Change in tax estimates</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Less: valuation allowance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">12,394</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">8,450</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Net provision for Federal income taxes</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table> -12394 -8450 0 0 12394 8450 0 0 0.21 0.21 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:90%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>December 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>December 31, </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>2023</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>2022</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Deferred tax asset attributable to:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Net operating loss carryover</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">258,844</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">246,450</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Less: valuation allowance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(258,844</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(246,450</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Net deferred tax asset</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table> 258844 246450 258844 246450 0 0 213844